0001493152-24-03162210-Q Processa Pharmaceuticals, Inc. 20240813202408131615391615391615391539 0 0001493152-24-031622 10-Q 53 20240630 20240813 20240813 Processa Pharmaceuticals, Inc. 0001533743 2834 451539785 DE 1231 10-Q 34 001-39531 241201682 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 Heatwurx, Inc. 20111028 10-Q 1 form10-q.htm false Q2 --12-31 0001533743 0001533743 2024-01-01 2024-06-30 0001533743 2024-08-01 0001533743 2024-06-30 0001533743 2023-12-31 0001533743 2024-04-01 2024-06-30 0001533743 2023-04-01 2023-06-30 0001533743 2023-01-01 2023-06-30 0001533743 us-gaap:CommonStockMember 2022-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2022-12-31 0001533743 us-gaap:RetainedEarningsMember 2022-12-31 0001533743 us-gaap:CommonStockMember 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-03-31 0001533743 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-12-31 0001533743 us-gaap:RetainedEarningsMember 2023-12-31 0001533743 us-gaap:CommonStockMember 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-03-31 0001533743 2024-03-31 0001533743 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533743 2023-01-01 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533743 2024-01-01 2024-03-31 0001533743 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533743 us-gaap:CommonStockMember 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-06-30 0001533743 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-06-30 0001533743 PCSA:ConsultingAgreementMember PCSA:SpartanCapitalSecuritesLLCMember 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001533743 2024-01-22 2024-01-22 0001533743 2024-01-22 0001533743 2024-01-21 0001533743 PCSA:PurchaseAgreementMember 2024-01-29 2024-01-30 0001533743 PCSA:PreFundedWarrantMember PCSA:PurchaseAgreementMember 2024-01-30 0001533743 us-gaap:WarrantMember PCSA:PurchaseAgreementMember 2024-01-30 0001533743 PCSA:PurchaseAgreementMember 2024-05-31 2024-05-31 0001533743 PCSA:SalesAgreementMember PCSA:AllianceGlobalPartnersMember srt:MaximumMember PCSA:ATMOfferingMember 2024-05-21 2024-05-21 0001533743 PCSA:PurchaseAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:PreFundedWarrantMember PCSA:PurchaseAgreementMember 2024-06-30 0001533743 us-gaap:WarrantMember PCSA:PurchaseAgreementMember 2024-06-30 0001533743 PCSA:PurchaseAgreementMember 2024-01-01 2024-06-30 0001533743 us-gaap:WarrantMember PCSA:PurchaseAgreementMember 2024-06-30 0001533743 PCSA:PlacementAgentMember 2024-06-30 0001533743 PCSA:ElionOncologyIncMember PCSA:LicenseAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:ConsultantMember PCSA:ConsultingAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:EmployeesAndConsultantsMember 2024-01-01 2024-06-30 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-06-28 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-06-30 0001533743 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001533743 us-gaap:RestrictedStockMember 2024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember PCSA:EmployeesMember 2024-06-28 2024-06-28 0001533743 PCSA:ServiceBasedRestrictedStockUnitsMember PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember PCSA:EmployeesMember 2024-06-28 2024-06-28 0001533743 PCSA:ServiceBasedRestrictedStockUnitsMember PCSA:EmployeesMember PCSA:ThreeYearVestingMember 2024-06-28 2024-06-28 0001533743 PCSA:FirstPerformanceBasedRSUMember PCSA:EmployeesMember 2024-06-28 2024-06-28 0001533743 PCSA:SecondPerformanceBasedRSUMember PCSA:NextGenerationCapecitabineCAPMember PCSA:EmployeesMember 2024-06-28 2024-06-28 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001533743 us-gaap:WarrantMember PCSA:OfferingMember 2024-06-30 0001533743 PCSA:ConsultingAgreementMember 2024-01-01 2024-06-30 0001533743 us-gaap:WarrantMember 2024-06-30 0001533743 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533743 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001533743 us-gaap:FacilityLeaseMember 2024-06-30 0001533743 us-gaap:EquipmentMember 2024-06-30 0001533743 PCSA:CorLystLLCMember 2024-04-01 2024-06-30 0001533743 PCSA:CorLystLLCMember 2023-04-01 2023-06-30 0001533743 PCSA:CorLystLLCMember 2024-01-01 2024-06-30 0001533743 PCSA:CorLystLLCMember 2023-01-01 2023-06-30 0001533743 PCSA:CorLystLLCMember 2024-06-30 0001533743 PCSA:CorLystLLCMember 2023-06-30 0001533743 PCSA:CROsMember 2024-06-30 0001533743 us-gaap:SubsequentEventMember 2024-07-16 2024-07-16 0001533743 us-gaap:SubsequentEventMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-16 2024-07-16 0001533743 us-gaap:SubsequentEventMember PCSA:ServiceBasedRSUMember 2024-07-16 2024-07-16 0001533743 PCSA:FirstPerformanceBasedRSUMember us-gaap:SubsequentEventMember 2024-07-16 2024-07-16 0001533743 us-gaap:SubsequentEventMember PCSA:FirstPerformanceBasedRSUMember 2024-07-16 2024-07-16 0001533743 us-gaap:SubsequentEventMember PCSA:SecondPerformanceBasedRSUMember 2024-07-16 2024-07-16 0001533743 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PCSA:Segments xbrli:pure

United States Securities and Exchange Commission Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) Â ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 Â or Â ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â Â For the transition period from ____ to ____ Â Commission File Number 001-39531 Â Processa Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Â Delaware Â 45-1539785 (State or other jurisdiction of incorporation or organization) Â (IRS Employer Identification No.) Â 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 (443) 776-3133 Â Securities registered pursuant to Section 12(b) of the Exchange Act: Â Title of Each Class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock, $0.0001 par value per share Â PCSA Â The Nasdaq Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Â Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Â Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ Â The number of outstanding shares of the registrant's common stock at August 1, 2024 was 3,256,944. Â Â Â Â Â PROCESSA PHARMACEUTICALS, INC. Â TABLE OF CONTENTS Â

Â 2 Â Part I. Financial Information Â Item 1: Financial Statements Â Processa Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (Unaudited) Â Â Â Â Â Â Â Â June 30, 2024Â Â December 31, 2023Â ASSETSÂ Â Â Â Â Â Â Â Current AssetsÂ Â Â Â Â Â Â Â Cash and cash equivalentsÂ $5,571,120Â Â $4,706,197Â Prepaid expenses and otherÂ Â 1,906,854Â Â Â 926,300Â Total Current AssetsÂ 7,477,974Â Â 5,632,497Â Â Â Â Â Â Â Â Property and Equipment, netÂ Â 2,276Â Â 2,554Â Â Â Â Â Â Â Â Other AssetsÂ Â Â Â Â Â Â Â Lease right-of-use assets, net of accumulated amortizationÂ Â 115,191Â Â 146,057Â Security depositÂ Â 5,535Â Â 5,535Â Total Other AssetsÂ 120,726Â Â 151,592Â Total AssetsÂ $7,600,976Â Â $5,786,643Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERS' EQUITYÂ Â Â Â Â Â Â Â Current LiabilitiesÂ Â Â Â Â Â Â Â Current maturities of lease liabilitiesÂ $93,181Â Â $83,649Â Accounts payableÂ Â 953,086Â Â 311,617Â Due to licensorÂ Â -Â Â 189,000Â Due to related partiesÂ Â -Â Â 39Â Accrued expensesÂ Â 505,397Â Â 146,274Â Total Current LiabilitiesÂ Â 1,551,664Â Â 730,579Â Non-current LiabilitiesÂ Â Â Â Â Â Â Â Non-current lease liabilitiesÂ Â 25,648Â Â 66,905Â Total LiabilitiesÂ Â 1,577,312Â Â 797,484Â Â Â Â Â Â Â Â Commitments and ContingenciesÂ -Â Â -Â Â Â Â Â Â Â Â Stockholders' EquityÂ Â Â Â Â Â Â Â Common stock, par value $0.0001, 100,000,000 shares authorized; 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023Â Â 287Â Â 129Â Additional paid-in capitalÂ Â 87,429,165Â Â 80,658,111Â Treasury stock at cost — 5,000 shares at June 30, 2024 and December 31, 2023Â Â (300,000)Â Â (300,000) Accumulated deficitÂ Â (81,105,788)Â Â (75,369,081) Total Stockholders' EquityÂ Â 6,023,664Â Â 4,989,159Â Total Liabilities and Stockholders' EquityÂ $7,600,976Â Â $5,786,643Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Â Processa Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Operating ExpensesÂ Â Â Â Â Â Â Â Â Â Â Â Research and development expensesÂ $1,730,444Â Â $1,688,164Â Â $3,269,555Â Â $3,342,509Â General and administrative expensesÂ Â 1,351,580Â Â 1,026,301Â Â 2,622,067Â Â 3,477,490Â Operating LossÂ Â (3,082,024)Â Â (2,714,465)Â Â (5,891,622)Â Â (6,819,999)Â Â Â Â Â Â Â Â Â Â Â Â Other Income (Expense), netÂ Â 71,698Â Â 101,900Â Â 154,915Â Â 185,361Â Net Operating Loss Before Income Tax BenefitÂ Â (3,010,326)Â Â (2,612,565)Â Â (5,736,707)Â Â (6,634,638) Income Tax BenefitÂ Â -Â Â -Â Â -Â Â -Â Net LossÂ Â $(3,010,326)Â Â $(2,612,565)Â Â $(5,736,707)Â Â $(6,634,638) Â Â Â Â Â Â Â Â Â Â Â Â Net Loss per Common Share - Basic and DilutedÂ Â $(1.01)Â Â $(1.94)Â Â $(2.11)Â Â $(5.34) Â Â Â Â Â Â Â Â Â Â Â Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and DilutedÂ Â 2,983,283Â Â 1,346,808Â Â 2,724,903Â Â 1,243,475Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 4 Â Processa Pharmaceuticals, Inc. Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Â Â SharesÂ Â AmountÂ Â CapitalÂ Â SharesÂ Â AmountÂ Â DeficitÂ Â TotalÂ Â Â Â Â Common StockÂ Â Paid-InÂ Â Treasury StockÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â SharesÂ Â AmountÂ Â DeficitÂ Â TotalÂ Balance at January 1, 2023Â Â 806,774Â Â $80Â Â $72,018,222Â Â (5,000)Â $(300,000)Â $(64,247,561)Â $7,470,741Â Stock-based compensationÂ Â 3,195Â Â 1Â Â 341,503Â Â -Â -Â -Â -Â -Â Â 341,504Â Shares issued in connection with capital raises, net of transaction costsÂ Â 421,611Â Â 42Â Â 6,352,035Â Â -Â -Â Â 6,352,077Â Net lossÂ Â -Â Â -Â Â -Â Â -Â -Â Â (4,022,073)Â Â (4,022,073) Balance, March 31, 2023Â Â 1,231,580Â Â 123Â Â 78,711,760Â Â (5,000)Â (300,000)Â Â (68,269,634)Â Â 10,142,249Â Stock-based compensationÂ Â -Â Â -Â Â 319,123Â Â -Â -Â -Â Â 319,123Â Warrants issued in connection with a consulting agreementÂ Â -Â Â -Â Â 1,310,875Â Â -Â -Â Â 1,310,875Â Net lossÂ Â -Â Â -Â Â -Â Â -Â -Â Â (2,612,565)Â Â (2,612,565) Balance, June 30, 2023Â Â 1,231,580Â Â $123Â Â $80,341,758Â Â (5,000)Â $(300,000)Â Â $(70,882,199)Â $9,159,682Â Â Â Â Â Â Â Â Â Â Â Â AdditionalÂ Â Â Â Â Â Common StockÂ Â Paid-InÂ Â Treasury StockÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â SharesÂ Â AmountÂ Â DeficitÂ Â TotalÂ Balance at January 1, 2024Â Â 1,291,000Â Â $129Â Â $80,658,111Â Â (5,000)Â $(300,000)Â Â $(75,369,081)Â $4,989,159Â Stock-based compensationÂ Â 13,176Â Â 1Â Â 167,642Â Â -Â -Â Â 167,643Â Shares issued in connection with capital raise, net of transaction costsÂ Â 1,555,555Â Â 156Â Â 6,282,274Â Â -Â -Â -Â -Â Â 6,282,430Â Shares issued in connection with license agreementÂ Â 5,000Â Â 1Â Â 188,999Â Â -Â -Â -Â -Â Â 189,000Â Settlement of stock awardÂ Â -Â Â -Â Â (8,561)Â Â -Â -Â -Â -Â Â (8,561) Shares withheld to pay income taxes on stock-based compensationÂ Â (3,750)Â Â (1)Â Â (9,923)Â Â -Â -Â -Â -Â Â (9,924) Net lossÂ Â -Â Â -Â Â -Â Â -Â -Â Â (2,726,381)Â Â (2,726,381) Balance, March 31, 2024Â Â 2,860,981Â Â 286Â Â 87,278,542Â Â (5,000)Â Â (300,000)Â Â (78,095,462)Â Â 8,883,366Â BalanceÂ Â 2,860,981Â Â 286Â Â 87,278,542Â Â (5,000)Â Â (300,000)Â Â (78,095,462)Â Â 8,883,366Â Stock-based compensationÂ Â 14,167Â Â 1Â Â 152,631Â Â -Â -Â -Â Â 152,632Â Shares withheld to pay income taxes on stock-based compensationÂ Â (1,265)Â Â -Â Â (2,008)Â Â -Â -Â -Â -Â Â (2,008) Net lossÂ Â -Â Â -Â Â -Â Â -Â -Â Â (3,010,326)Â Â (3,010,326) Balance, June 30, 2024Â Â 2,873,883Â Â $287Â Â $87,429,165Â Â (5,000)Â $(300,000)Â $(81,105,788)Â $6,023,664Â BalanceÂ Â 2,873,883Â Â $287Â Â $87,429,165Â Â (5,000)Â $(300,000)Â $(81,105,788)Â $6,023,664Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 5 Â Processa Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Â Â Â 2024Â Â 2023Â Â Â Six Months Ended June 30,Â Â 2024Â Â 2023Â Cash Flows From Operating ActivitiesÂ Â Â Â Â Â Â Â Net lossÂ Â $(5,736,707)Â Â $(6,634,638) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Â DepreciationÂ Â 278Â Â -Â Non-cash lease expense for right-of-use assetsÂ Â 42,670Â Â 39,982Â Stock-based compensationÂ Â 320,275Â Â 660,627Â Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreementÂ Â -Â Â 1,310,875Â Net changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Prepaid expenses and otherÂ Â (980,554)Â Â 662,984Â Operating lease liabilityÂ Â (41,228)Â Â (38,233) Accounts payableÂ Â 641,469Â Â (88,526) Due to related partiesÂ Â (39)Â Â (51) Accrued expensesÂ Â 359,123Â Â (91,559) Net cash used in operating activitiesÂ Â (5,394,713)Â Â (4,178,539) Â Â Â Â Â Â Â Â Cash Flows From Financing ActivitiesÂ Â Â Â Â Â Â Â Net proceeds from issuance of stockÂ Â 6,282,430Â Â 6,352,077Â Shares withheld to pay taxes on stock-based compensationÂ Â (11,932)Â Â -Â Settlement of stock awardÂ Â (8,561)Â Â -Â Payment of finance lease obligationÂ Â (2,301)Â Â -Â Net cash provided by financing activitiesÂ Â 6,259,636Â Â 6,352,077Â Â Â Â Â Â Â Â Â Net Increase in CashÂ Â 864,923Â Â 2,173,538Â Cash and Cash Equivalents — Beginning of PeriodÂ Â 4,706,197Â Â 6,503,595Â Cash and Cash Equivalents — End of PeriodÂ $5,571,120Â $8,677,133Â Â Â Â Â Â Â Â Â Non-Cash Financing ActivitiesÂ Â Â Â Â Â Â Â Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensorÂ $189,000Â $-Â Â Â Â Â Â Â Â Right-of-use assetÂ $11,804Â Â $-Â Financing lease liabilityÂ Â (11,804)Â Â -Â NetÂ $-Â $-Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 6 Â Processa Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) Â Note 1 â€" Organization and Summary of Significant Accounting Policies Â Organization Â We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy ("NGC") drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the

metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts. Â On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split of our common stock, par value $0.0001 per share (the â€œReverse Stock Splitâ€). Pursuant to the Certificate of Amendment, our issued common stock decreased from 24,706,474 shares to 1,291,000 shares and our outstanding common stock decreased from 24,606,474 to 1,286,000. The Reverse Stock Split did not affect our authorized common stock of 100,000,000 shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split. Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) for interim financial information and with the instructions of the Securities and Exchange Commission (â€œSECâ€) on Form 10-Q and Article 8 of Regulation S-X. Â Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Â Liquidity Â Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. Â 7 Â Â We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock. Â In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the â€œRegistration Statementâ€), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings, and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the â€œSales Agreementâ€) between us and A.G.P./Alliance Global Partners (the â€œSales Agentâ€), through which we may issue and sell in a registered â€œat the market offeringâ€ shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the â€œATM Offeringâ€). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement. Â At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business plans, we believe these funds will satisfy our operating needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations. Â We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholdersâ€™ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed. Â Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above. Â Use of Estimates Â In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on managementâ€™s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows. Â 8 Â Â Income Taxes Â We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal. Â Under ACS 740-270 Income Taxes â€" Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses. Â Concentration of Credit Risk Â Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (â€œFDICâ€) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits. Â Recent Accounting Pronouncements Â From time to time, the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (â€œASUâ€). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations. Â Note 2 â€" Stockholdersâ€™ Equity Â Preferred Stock Â There were no issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023. Â Common Stock Â During the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the â€œPre-Funded Warrantsâ€), and warrants to purchase up to 1,555,555 shares of our common stock (the â€œCommon Warrantsâ€) in a public offering (the â€œOfferingâ€). The Common Warrants have an exercise price of $4.50, are immediately exercisable and expire on January 30, 2029. The shares of common stock were offered at a combined public offering price of $4.50 per share and accompanying Common Warrant and $4.4999 per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $0.0001 and were exercised in full simultaneously with the closing of the Offering in exchange for 1,079,555 shares of our common stock. Gross proceeds in connection with the Offering were $7.0 million. We received $6.3 million in net proceeds from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement agent warrants to purchase 62,222 shares of common stock, exercisable at $5.625 per share that expire on February 1, 2027. Â During the six months ended June 30, 2024, we also issued: 5,000 shares of common stock to Elion Oncology, Inc. (â€œElionâ€) in satisfaction of the third milestone event under the license agreement; 10,000 shares of common stock to a consultant in accordance with their consulting agreement; and 12,328 shares of common stock to certain employees and consultants, net of 5,015 shares of common stock withheld for income taxes owed upon distribution of the shares. Â 9 Â Â Note 3 - Stock-based Compensation Â On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the â€œ2019 Planâ€). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of 800,000 shares of our common stock. At June 30, 2024, we have 503,129 shares available for future grants. Â Stock Compensation Expense Â We recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows: Â Schedule of Stock-based Compensation Expense Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and developmentÂ Â $45,583Â Â $102,678Â Â $76,704Â Â $209,526Â General and administrativeÂ Â 107,049Â Â 216,445Â Â 243,571Â Â 451,101Â TotalÂ Â $152,632Â Â $319,123Â Â $320,275Â Â $660,627Â Â Stock Options Â Stock options to purchase 4,245 shares of common stock with a weighted-average exercise price of $336.00 expired during the six months ended June 30, 2024. At June 30, 2024, we had outstanding and exercisable options for the purchase of 2,747 shares with a weighted average exercise price of $409.09 and a weighted average remaining contractual life of 4.2 years. At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock options. Â Restricted Stock Awards Â During the six months ended June 30, 2024, we vested 1,250 Restricted Stock Awards (â€œRSAsâ€) with a weighted average grant-date fair value of $9.26 per share. We had no RSAs outstanding at June 30, 2024. Â Restricted Stock Units Â Activity with respect to our Restricted Stock Units (â€œRSUsâ€) during the six months ended June 30, 2024 was as follows: Â Schedule of Restricted Stock Units (â€œRSUsâ€) Activity Â Â Number of sharesÂ Â Weighted- average grant-date fair value per shareÂ Outstanding at January 1, 2024Â Â 222,722Â Â $45.82Â GrantedÂ Â 39,202Â Â 2.24Â ForfeitedÂ Â (10,775)Â Â 58.37Â IssuedÂ Â (12,328)Â Â 99.86Â Outstanding at June 30, 2024Â Â 238,821Â Â 35.31Â Vested and unissuedÂ Â 143,793Â Â 50.71Â Â Â Â Â Â Â Â Â Unvested at June 30, 2024Â Â 95,028Â Â $12.00Â Â On June 28, 2024, we granted RSUs for the future issuance of 39,202 shares of common stock to our employees which vest accordingly: RSUs for the future issuance of 14,969 shares of common stock vest on January 1, 2025; RSUs for the future issuance of 18,173 shares of common stock vest over a three-year period upon meeting service requirements; RSUs for the future issuance of 3,030 shares of common stock vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of 3,030 shares of common stock vest upon dosing the first patient in our Phase 2 study in NGC-Cap. Â 10 Â Â At June 30, 2024, unrecognized stock-based compensation expense of approximatelyÂ $538,000 for RSUs is expected to be fully recognized over a weighted average period of 1.7 years. The unrecognized expense excludes approximately $420,000 of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time. Â Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights. Â Warrants Â During the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase 1,617,777 shares of common stock as part of the Offering (see Note 2). Warrants to purchase 5,000 shares of our common stock expired unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of 15,000 shares of our common stock in exchange for a payment of $10,000. Â At June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of 1,778,284 shares with a weighted average exercise price of $6.17 and a weighted average remaining contractual life of 4.3 years. All the outstanding stock purchase warrants are exercisable as of June 30, 2024. We did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2024. Â Note 4 â€" Net Loss per Share of Common Stock Â Net Loss Per Share Â Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have had an anti-dilutive effect on net loss per share. Â The computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows: Â Schedule of Net Loss Per Share Basic and Diluted Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Basic and diluted net loss per share:Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss available to common stockholdersÂ Â $(3,010,326)Â Â $(2,612,565)Â Â $(5,736,707)Â Â $(6,634,638)Â Weighted average number of common shares-basic and dilutedÂ Â 2,983,283Â Â 1,346,808Â Â 2,724,903Â Â 1,243,475Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per shareÂ Â $(1.01)Â Â $(1.94)Â Â $(2.11)Â Â $(5.34)Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Weighted-average number of common shares outstanding â€" basic and dilutedÂ Â 2,849,192Â Â 1,217,095Â Â 2,590,530Â Â 1,114,324Â Weighted-average number of vested RSUs â€" basic and dilutedÂ Â 134,091Â Â 129,713Â Â 134,373Â Â 129,151Â Weighted-average number of common shares-basic and dilutedÂ Â 2,983,283Â Â 1,346,808Â Â 2,724,903Â Â 1,243,475Â Our diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded 1,876,059 and 254,314 of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended. Â Note 5 â€" Leases Â We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% in determining the present value of the lease payments based on the information available at the lease commencement date. Â 11 Â Â Lease costs included in our condensed consolidated statements of operations totaled approximately $23,000 and $24,000 for the three months ending June 30, 2024 and 2023, respectively, and approximately $45,000 and $49,000 for the six months ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as follows at June 30, 2024: Â Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases Remaining lease term (years) for our facility leaseÂ

1.3 Remaining lease term (years) for our equipment lease 1.6 Weighted average discount rate for our facility and equipment leases 8.0% Annual lease liabilities for the operating lease were as follows at June 30, 2024: Schedule of Annual Lease Liabilities for all Operating Leases 2024 $45,797 2025 70,040 Total lease payments 115,837 Less: Interest (6,511) Present value of lease liabilities 109,326 Less: current maturities (87,495) Non-current lease liability $21,831 Annual lease liabilities for the financing lease were as follows at June 30, 2024: Schedule of Annual Lease Liabilities for all Financing Leases 2024 $3,232 2025 6,820 2026 488 Total lease payments 10,540 Less: Interest (1,037) Present value of lease liabilities 9,503 Less: current maturities (5,686) Non-current lease liability $3,817 Note 6 — Related Party Transactions CorLyst, LLC ("CorLyst") reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded approximately $27,000 and $34,000 of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $50,000 and $64,000 for the six months ended June 30, 2024 and 2023, respectively. No amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst is a shareholder. Note 7 — Commitments and Contingencies Purchase Obligations We enter into contracts in the normal course of business with contract research organizations ("CROs") and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $14.3 million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining clinical trials. Note 8 — Subsequent Event On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). Mr. Skibsted has nearly 30 years of experience in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target bonus of 35% of his base compensation. In addition, the Compensation Committee awarded 28,000 RSUs to Mr. Skibsted, which vest accordingly: 14,000 RSUs vest on July 16, 2025; 7,000 RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa's outstanding shares of stock at the then current market price) of at least $30 million; and 7,000 RSUs vest upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment agreement. 12 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation Forward Looking Statements This Quarterly Report on Form 10-Q contains "forward-looking statements" that reflect, when made, the Company's expectations or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the words "believe," "anticipate," "expect," "estimate," "intend," "project," "will be," "will continue," "will likely result," or other similar words and phrases. Similarly, statements herein that describe the Company's objectives, plans or goals also are forward-looking statements. Actual results could differ materially from those projected, implied or anticipated by the Company's forward-looking statements. Some of the factors that could cause actual results to differ include: our limited operating history, limited cash and history of losses; our ability to achieve profitability; our ability to obtain adequate financing to fund our business operations in the future; our ability to secure required FDA or other governmental approvals for our product candidates and the breadth of the indication sought; the impact of competitive or alternative products, technologies and pricing; whether we are successful in developing and commercializing our technology, including through licensing; the adequacy of protections afforded to us and/or our licensors by the anticipated patents that we own or license and the cost to us of maintaining, enforcing and defending those patents; our and our licensors' ability to protect non-patented intellectual property rights; our exposure to and ability to defend third-party claims and challenges to our and our licensors' anticipated patents and other intellectual property rights; and our ability to continue as a going concern. For a discussion of these and all other known risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which is available on the SEC's website at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q to reflect events or circumstances after the date hereof. For purposes of this Management's Discussion and Analysis of Financial Condition and Results of Operations, references to the "Company," "we," "us" or "our" refer to the operations of Processa Pharmaceuticals, Inc. and its direct and indirect subsidiaries for the periods described herein. Overview We are a clinical-stage biopharmaceutical company focused on utilizing our Regulatory Science Approach, which includes the principles associated with FDA's Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy ("NGC") oncology drug products. Our mission is to provide better treatment options than those that presently exist by extending a patient's survival and/or improving a patient's quality of life. This is achieved by improving upon FDA-approved, widely used oncology drugs or the cancer-killing metabolites of these drugs by altering how they are metabolized and/or distributed in the body, including how they are distributed to the actual cancer cells. Our Regulatory Science Approach was conceived in the early 1990s when the founders of Processa and other faculty at the University of Maryland worked with the FDA to develop multiple FDA Guidance Documents. Regulatory science is the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products. Over the last 30 years, two of our founders, Dr. David Young and Dr. Sian Bigora, have expanded the original regulatory science concept by adding focused pre-clinical and clinical studies to justify the benefit-risk assessment required for FDA approval when designing the development programs of new drug products. Our Regulatory Science Approach identifies the scientific information that the FDA requires to determine whether the benefit outweighs the risk of a drug in a specific population of patients and at a specific dosage regimen for a specific drug product. The studies are designed to obtain the necessary scientific information to support the regulatory decision. Recently, the FDA has taken steps to define some of the regulatory science required for the FDA approval of oncology products. Through the FDA's Project Optimus Oncology Initiative and the related Draft Guidance on determining the "optimal" dosage regimen for an oncology drug, the FDA has chosen to make the development of oncology drugs more science-based than in the past. Since the principles of the FDA's Project Optimus and the related Draft Guidance have been used by our Regulatory Science Approach in a number of non-oncology drugs in the past, our experience with the principles of Project Optimus differentiates us from other biotechnology companies by focusing us not only on the clinical science, but also on the equally important regulatory process. We believe utilizing our Regulatory Science Approach provides us with three distinct advantages: — greater efficiencies (e.g., the right trial design and trial readouts); — greater possibility of drug approval by the FDA or other regulatory authorities; and — greater ability to evaluate the benefit-risk of a drug compared to existing therapy, which allows prescribers to provide better treatment options for each patient. Our strategic prioritization is to advance our pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities that change the metabolism, distribution and/or elimination of already FDA-approved cancer drugs, or their active metabolites, while maintaining the drug's proven mechanism of action in killing cancer cells. We believe our NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts — capecitabine, gemcitabine, and irinotecan. 13 Our Drug Pipeline Our pipeline currently consists of NGC-Cap, NGC-Gem and NGC-Iri (also identified as PCS6422, PCS3117 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). The non-oncology drugs are not included in the pipeline chart above, as we are exploring our options for those drugs, which may include out-licensing or partnership opportunities. A summary of each drug is provided below. Next Generation Chemotherapy Historically, much of oncology drug development has searched for novel or different ways to treat cancer. Our approach is to take three current FDA-approved cancer drugs, e.g. capecitabine, gemcitabine and irinotecan, and modify and improve how the human body metabolizes and/or distributes these NGC treatments compared to their presently approved counterpart chemotherapy drugs while maintaining the cancer-killing mechanism of action; thus, our reason for calling our drugs Next Generation Chemotherapy treatments. Part of the development includes determining the optimal dosage regimen based on the dose-response relationship as described in the FDA's Project Optimus Initiative and Draft Optimal Dosage Regimen Oncology Guidance. To date, we have data that we believe suggests our NGC treatments are likely to have a better safety-efficacy profile than the current widely used marketed counterpart drugs, not only potentially making the development and approval process more efficient, but also clearly differentiating our NGC treatments from the existing treatment. We believe our NGC treatments have the potential to extend the survival and/or quality of life for more patients diagnosed with cancer while decreasing the number of patients who are required to dose-adjust or discontinue treatment because of side effects or lack of response. Next Generation Chemotherapy Pipeline — Next Generation Capecitabine ("NGC-Cap") is a combination of PCS6422 and a lower dose of the FDA-approved cancer drug capecitabine. PCS6422 is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase ("DPD"). DPD metabolizes 5-Fluorouracil ("5-FU"), the major metabolite of capecitabine and widely used itself as an intravenous chemotherapeutic agent in many types of cancer, to multiple metabolites classified as catabolites. These catabolites do not have any cancer-killing properties but frequently cause dose-limiting side effects that may require dose adjustments or discontinuation of therapy. Capecitabine, as presently prescribed and FDA-approved, forms the cancer drug 5-FU which is then further metabolized to anabolites (which kill both cancer cells and normal duplicating cells) and catabolites (which cause side effects and have no cancer killing properties). When capecitabine is given in combination with PCS6422 in NGC-Cap, PCS6422 significantly changes the metabolism of 5-FU, which results in a change in the distribution of 5-FU within the body. Due to this change in metabolism and the overall metabolite profile of anabolites and catabolites, the side effect and efficacy profile of NGC-Cap has been found to be different from capecitabine given without PCS6422. Since the potency of NGC-Cap is also greater than FDA-approved capecitabine based on the 5-FU systemic exposure per mg of capecitabine administered, the amount of capecitabine anabolites formed from 1 mg of capecitabine administered in NGC-Cap will, therefore, be much greater than formed from the administration of 1 mg of existing capecitabine. The Phase 1B trial in patients with advanced refractory gastrointestinal tract tumors demonstrated that the irreversible inhibition of DPD by PCS6422 could alter the metabolism, distribution and elimination of 5-FU, making NGC-Cap significantly (up to 50 times) more potent than capecitabine alone and potentially leading to higher levels of anabolites which can kill replicating cancer and normal cells. By administering NGC-Cap to cancer patients, the balance between anabolites and catabolites changes depending on the dosage regimens of PCS6422 and capecitabine used, making the efficacy-safety profile of NGC-Cap different than that of FDA-approved capecitabine and requiring further evaluation of the PCS6422 and capecitabine regimens to determine the optimal NGC-Cap regimens for patients. 14 In order for NGC-Cap to provide a safer and more efficacious profile for cancer patients compared to existing chemotherapy, understanding how the different regimens of PCS6422 and capecitabine may affect the systemic and tumor exposure to the anabolites, as well as the systemic exposure to the catabolites, is required. This can be achieved by following the timeline of DPD irreversible inhibition and the formation of new DPD using the plasma concentrations of 5-FU and its catabolites. In an effort to better estimate the timeline of DPD inhibition and formation of new DPD, we modified the protocol for the Phase 1B trial and began enrolling patients in the amended Phase 1B trial in April 2022. On November 1, 2022, we announced that data from the Phase 1B trial identified multiple dosage regimens with potentially better safety and efficacy profiles than currently existing chemotherapy regimens. Since 5-FU exposure is dependent on both the PCS6422 regimen and the capecitabine regimen, safe regimens were identified as well as regimens that cause dose-limiting toxicities ("DLTs"). One of the early regimens in the Phase 1B trial did cause DLTs in two patients, one of whom died. No other DLTs were noted in the study. The Phase 1B trial has now completed enrollment and we are currently conducting trial close-out activities. We submitted a new IND for the treatment of advanced and metastatic breast cancer and received IND clearance from the FDA on July 24, 2024. The Phase 2 trial is currently being initiated and will be a global multicenter, open-label, adaptive design trial comparing two different doses of NGC-Cap to FDA-approved monotherapy capecitabine in approximately 60 to 90 patients with advanced or metastatic breast cancer. The trial is designed to evaluate the safety-efficacy profile of NGC-Cap versus monotherapy capecitabine, to determine the potential optimal dosage regimens of NGC-Cap as required by the FDA Project Optimus Initiative. Our license agreement with Elion for NGC-Cap requires us to use commercially reasonable efforts, at our sole cost and expense, to research, develop and commercialize products in one or more countries, including meeting specific diligence milestones that include dosing a first patient with a product in a Phase 2 or 3 clinical trial on or before October 2, 2024. We expect the first patient to be dosed before the conclusion of the third quarter of 2024, ahead of the required diligence milestone. — NGC-Gem is a cytidine analog similar to gemcitabine (Gemzar®), but different enough in chemical structure that some patients are more likely to respond to PCS3117 than gemcitabine. In addition, we believe those patients inherently resistant or who acquire resistance to gemcitabine are likely not to be resistant to NGC-Gem. The difference in response occurs because NGC-Gem is metabolized to its active metabolite through a different enzyme system than gemcitabine. We continue to evaluate the potential use of NGC-Gem in patients with pancreatic and other potential cancers and to evaluate ways to identify patients who are more likely to respond to NGC-Gem than gemcitabine. We plan to meet with the FDA to discuss potential trial designs including implementation of the Project Optimus initiative as part of the design. Similar to NGC-Cap, we will need to obtain additional funding before we can begin the Phase 2 trial for NGC-Gem. 15 Our license agreement with Ocuphire Pharma, Inc. ("Ocuphire") for NGC-Gem requires us to use commercially reasonable efforts, at our sole cost and expense to oversee such commercialization efforts, to research, develop and commercialize products in one or more countries, including meeting specific diligence milestones that consist of: (i) dosing a patient in a clinical trial prior to June 16, 2024; and (ii) dosing a patient in a pivotal clinical trial or in a clinical trial for a second indication of the drug prior to June 16, 2026. We are currently in discussions with Ocuphire to extend these deadlines. — NGC-Iri is an analog of SN38 (SN38 is the active metabolite of irinotecan) and should have an improved safety/efficacy profile in every type of cancer that irinotecan is presently used. The manufacturing process and sites for drug substance and drug product are presently being evaluated and IND-enabling toxicology studies will then be initiated. In addition, we are defining the potential paths to approval, which include defining the targeted patient population and the type of cancer. In 2025, we plan to expand the preclinical analysis, including additional preclinical efficacy and toxicity studies; evaluate manufacturing options for PCS11T; and conduct chemistry, manufacturing and control (CMC) activities and pre-IND enabling studies. We are focused on drug products that improve the survival and/or quality of life for patients by improving the safety and/or efficacy of the drug in a targeted patient population, while providing a more efficient and probable path to FDA approval and differentiating our drugs from those on the market or are currently being developed. Other Drugs in Our Pipeline In 2023, we completed our Phase 2A trial for PCS12852 in gastroparesis patients with positive results. Additionally, in February 2023, due primarily to the inability to identify and enroll patients in our rare disease Phase 2 trial for PCS499 in ulcerative Necrobiosis Lipoidica, we decided to cease further enrollment in the PCS499 trial and terminated the trial. We did not experience any safety concerns during the conduct of either the PCS12852 or PCS499 trial. We continue to evaluate options to monetize these non-core drug assets, which may include out-licensing or partnering these assets with one or more third parties. Recent Developments Reverse Stock Split On January 22, 2024, we effected a 1-for-20 reverse stock split, reducing the number of our common shares issued on that date from 24,706,474 shares to 1,291,000 shares. There is no corresponding reduction in the number of authorized shares of common stock and no change in the par value per share. All share and per share amounts and conversion and exercise prices presented herein have been adjusted retroactively to reflect this change. 16 Public Offering On January 30, 2024, we raised gross proceeds of $7.0 million (net proceeds of $6.3 million) from the sale of 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock and warrants to purchase 1,555,555 shares of our common stock in a public offering, as described in Note 2. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock. We are using the net proceeds from this financing for continued research and development for NCG-Cap, and working capital and general corporate purposes. ATM Offering In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings, and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the

Registration Statement.

New Chief Financial Officer

On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). Mr. Skibsted has nearly 30 years of experience in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target bonus of 35% of his base compensation. In addition, the Compensation Committee awarded 28,000 RSUs to Mr. Skibsted, which vest accordingly: 14,000 RSUs vest on July 16, 2025; 7,000 RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa's outstanding shares of stock at the then current market price) of at least $30 million; and 7,000 RSUs vest upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment agreement.

Results of Operations

Comparison of the three and six months ended June 30, 2024 and 2023

The following table summarizes our net loss during the periods indicated:

	Three Months Ended June 30,			Six Months Ended June 30,		
	2024	2023	Change	2024	2023	Change
Operating Expenses						
Research and development expenses	$1,730,444	$1,688,164	$42,280	$3,269,555	$3,342,509	$(72,954)
General and administrative expenses	1,351,580	1,026,301	325,279	2,622,067	3,477,490	(855,423)
Operating Loss	(3,082,024)	(2,714,465)		(5,891,622)	(6,819,999)	
Other Income (Expense), net	71,698	101,900	(30,141)	154,915	185,361	(30,309)
Net Operating Loss Before Income Tax Benefit	(3,010,326)	(2,612,565)		(5,736,707)	(6,634,638)	
Income Tax Benefit	-	-	-	-	-	
Net Loss	$(3,010,326)	$(2,612,565)		$(5,736,707)	$(6,634,638)	

Revenues

We do not currently have any revenue under contract or any immediate sales prospects.

Research and Development Expenses

Our research and development costs are expensed as incurred. Research and development expenses include (i) program and testing related expenses including external consulting and professional fees related to the product testing and our development activities and (ii) internal research and development staff salaries and other payroll costs including stock-based compensation, payroll taxes and employee benefits.

17

Costs for the three- and six-month periods for the periods ended June 30, 2024 and 2023 were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Research and development salaries and benefits	$468,724	$502,626	$976,554	$1,048,294
Preclinical, clinical trial and other costs	1,261,720	1,185,538	2,293,001	2,294,215
Total	$1,730,444	$1,688,164	$3,269,555	$3,342,509

During the three months ended June 30, 2024, our preclinical, clinical trial and other costs increased when compared to the same period in 2023. This was attributable to an increase of approximately $146,000 for ongoing testing and related expenses related to our Phase 1B trial for NGC-Cap and the IND/initiation of our Phase 2 trial for NGC-Cap and offset by a decrease in professional fees of approximately $70,000, mostly attributable to a decrease in patent-related legal fees. During the same period in 2023, in addition to clinical trial costs for NGC-Cap, we were incurring closing costs in our clinical trial for PCS12852 and PCS499. We also had an approximately $23,000 increase in salaries and related costs during the three months ended June 30, 2024 when compared to the same period in 2023 due to one-time bonuses and increased salary rates for the research and development team in 2024. This was offset by a decrease in stock-based compensation of approximately $57,000 as we waited for shareholder approval to increase the number of shares available under the 2019 Plan. During the six months ended June 30, 2024, we had increases in testing and related expenses of approximately $132,000, and in salaries and related costs of approximately $61,000, when compared to the same period in 2023. These increases were offset by decreases in professional fees of approximately $133,000 and in stock-based compensation of approximately $133,000. The reasons for the changes between the six-month periods in 2024 and 2023 are the same as the reasons between the three-month periods in 2024 and 2023. On July 24, 2024 we received approval of our IND for our Phase 2 trial for NGC-Cap in breast cancer. As we begin this Phase 2 trial and complete our Phase 1B clinical trial for NGC-Cap, we anticipate our research and development costs will increase. We will also continue incurring nominal costs for NGC-Gem as we prepare to meet with the FDA to discuss potential study designs and for NGC-Iri should we decide to conduct IND-enabling and toxicology studies. The funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include, but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically assess the scientific progress and merits of the programs to determine if continued research and development is economically viable. Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization. Our clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. We estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses and expensed when the services are rendered.

General and Administrative Expenses

Our general and administrative expenses for the three months ended June 30, 2024 increased by approximately $325,000 to $1.4 million from $1.0 million for the three months ended June 30, 2023. This increase was due primarily as a result of an approximately $308,000 increase in professional fees, mostly attributable to an increase of legal fees; an approximately $115,000 increase in salaries and other payroll-related costs from increased salary rates, primarily paid to our executive officers; and a net increase of approximately $17,000 in travel, office and other miscellaneous expenses. These increases were offset by a decrease in employee stock-based compensation of approximately $123,000. We also received approximately $8,000 less in reimbursements from CorLyst during the three months ended June 30, 2024 when compared to the same period in 2023.

18

During the six months ended June 30, 2024, our general and administrative expenses decreased by approximately $855,000 to $2.6 million from $3.5 million for the six months ended June 30, 2023. This was due primarily to a decrease in professional fees of approximately $955,000 as a result of the non-recurring expense that was incurred during 2023 in connection with the stock purchase warrant granted to the placement agent for our registered direct offering in February 2023; and a decrease in employee stock-based compensation of approximately $247,000 as we waited for shareholder approval to increase the number of shares available under the 2019 Plan. These decreases were primarily offset by increases in salaries and other payroll-related expenses of approximately $296,000 and in office and other related expenses of approximately $37,000. We also received approximately $14,000 less in reimbursements from CorLyst during the six months ended June 30, 2024 when compared to the same period in 2023.

Other Income, net

Other income represents interest income of approximately $72,000 and $102,000 for the three months ended June 30, 2024 and 2023, respectively, and approximately $155,000 and $185,000 for the six months ended June 30, 2024 and 2023, respectively.

Income Tax Benefit

We did not recognize any income tax benefit for the three or six months ended June 30, 2024 or 2023.

Cash Flows

The following table sets forth our sources and uses of cash and cash equivalents for the six months ended June 30, 2024 and 2023:

	Six months ended June 30,	
	2024	2023
Net cash (used in) provided by:		
Operating activities	$(5,394,713)	$(4,178,539)
Financing activities	6,259,636	6,352,077
Net increase in cash	$864,923	$2,173,538

Net cash used in operating activities – We used net cash in our operating activities of $5,394,713 and $4,178,539 during the six months ended June 30, 2024 and 2023, respectively. The increase in cash used in operating activities was primarily attributable to the prepayment of expenses paid to our CRO for our Phase 2 trial for NGC-Cap during the six months ended June 30, 2024. As we continue our development of NGC-Cap and evaluate the other NGC drugs in our portfolio, we anticipate our research and development efforts and ongoing general and administrative costs will continue to generate negative cash flows from operating activities for the foreseeable future. As we begin our Phase 2 clinical trial for NGC-Cap in the second half of 2024, we anticipate our clinical trial costs will increase when compared to prior periods since our current activities are related primarily to the completion of our Phase 1b trial for NGC-Cap.

Net cash provided by financing activities – During the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock, all of which were exercised into shares of common stock, and warrants to purchase up to 1,555,555 shares of our common stock pursuant to a public offering for net proceeds of $6.3 million. We also used cash classified as financing activities of $12,000 to pay income taxes owed on stock-based compensation, $8,600 for the settlement of a stock award and $2,300 for payments owed under a financing lease obligation.

19

During the six months ended June 30, 2023, we raised net proceeds of $6.4 million from the sale of 421,611 shares of our common stock.

Liquidity

During the six months ended June 30, 2024, we began initiation activities for our Phase 2 trial for NGC-Cap in breast cancer. At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business and drug development plans, we believe will satisfy our operating needs into late 2024. Absent additional funding, our current cash and cash equivalents will not be sufficient to fund our planned operations for a period of one year or more after the date that these condensed consolidated financial statements were available to be issued based on the timing and amount of our projected net loss from continuing operations and the related amount of cash to be used in operating activities during that period of time. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions.

We have incurred losses since inception, currently devoting substantially all of our efforts toward research and development of our next generation chemotherapy drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024 in which we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations. Further, in May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Contractual Obligations and Commitments

There have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Off Balance Sheet Arrangements

At June 30, 2024, we did not have any off-balance sheet arrangements.

20

Critical Accounting Policies and Use of Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We believe that the estimates, assumptions and judgments involved in the accounting policies described in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our most recent Annual Report on Form 10-K have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely events or circumstances that would result in materially different amounts being reported. There have been no changes in our critical accounting policies from those included in our most recent Annual Report on Form 10-K.

Recently Issued Accounting Pronouncements

We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 3 is not applicable to us as a smaller reporting company and has been omitted.

Item 4. Controls and Procedures

At June 30, 2024, management, with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of its disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at June 30, 2024 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect the Company's internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

As of the date of this report, to our knowledge, there are no legal proceedings or regulatory actions material to us to which we are a party, or have been a party to, or of which any of our property is or was the subject matter of, and no such proceedings or actions are known by us to be contemplated, except as provided below: As previously disclosed in our Current report on Form 10-Q for the period ended March 31, 2024, on May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and Elion as a result of the Company's alleged breach thereof. The Company believes that Elion's claims are without merit and disputes that the license agreement has been validly terminated. On May 10, 2024, the Company filed a summons with notice for damages, declaratory and injunctive relief against Elion in New York State Court. On June 14, 2024, Elion filed a demand for complaint. On July 5, 2024, the Company filed a complaint seeking monetary damages, declaratory judgement and injunctive relief. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it determines are appropriate.

21

Item 1A. Risk Factors

There have been no material changes to our risk factors as described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, other than the addition of the following risk factor: Our licenses are subject to termination by the licensor in certain circumstances. Our rights to practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the terms of those licenses and not terminating them. Our licenses may be terminated by the licensor if we are in material breach of certain terms or conditions of the license agreement or in certain other

circumstances. Our license agreements each include provisions that allow the licensor to terminate the license if (i) we breach any payment obligation or other material provision under the agreement and fail to cure the breach within a fixed time following written notice of termination; (ii) we or any of our affiliates, licensees or sublicensees directly or indirectly challenge the validity, enforceability, or extension of any of the licensed patents; or (iii) we declare bankruptcy or dissolve. The majority of license agreements require us to satisfy due diligence milestones that relate to the development of new products containing the licensed drug or the agreement may be terminated by such counterparty. Our rights under these licenses are subject to our continued compliance with the terms of the license, including the payment of royalties due under the licenses. Termination of any of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the patents we have licensed, determining the scope of the license and related royalty obligations can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from producing and selling some or all of our products. Â As previously disclosed in our Current Report on Form 10-Q for the period ended March 31, 2024, on May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between us and Elion as a result of the Companyâ€™s alleged breach thereof. The Company believes that Elionâ€™s claims are without merit and disputes that the license agreement has been validly terminated. On May 10, 2024, the Company filed a summons with notice for damages, declaratory and injunctive relief against Elion in New York State Court. On June 14, 2024, Elion filed a demand for complaint. On July 5, 2024, the Company filed a complaint seeking monetary damages, declaratory judgement and injunctive relief. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it determines are appropriate. Â If we are unsuccessful or are unable to enforce our rights under the license agreement, our business and results of operations may be adversely affected. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â (a) Recent Sale of Unregistered Securities Â On June 6, 2024, we issued 10,000 shares of common stock to Paramount Advisors, LLC in connection with a consulting agreement. The sale of shares was exempt from the registration requirements of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), in reliance on Section 4(a)(2) of the Securities Act. Â There were no other sales of unregistered securities during the three months ended June 30, 2024. Â (b) Use of Proceeds from Public Offering of Common Stock Â None. Â (c) Issuer Purchases of EquityÂ Securities Â We did not repurchase any shares of our common stock during the six months ended June 30, 2024. Â Item 3. Defaults Upon Senior Securities Â None. Â Item 4. Mine Safety Disclosures Â Not applicable. Â 22 Â Item 5. Other Information Â During the three months ended June 30, 2024, none of our directors or officers adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K. Â Item 6. Exhibits Â SEC Ref. No. Â Title of Document 1.1 Â Sales Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed on May 21, 2024) 10.1# Â Employment Agreement dated July 16, 2024 by and between Russell Skibsted and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 17, 2024) 31.1* Â Rule 153-14(a) Certification by Principal Executive Officer 31.2* Â Rule 153-14(a) Certification by Principal Financial Officer 32.1*++ Â Section 1350 Certification of Principal Executive Officer and Principal Financial Officer 99.1 Â XBRL Files 101.INS Â Inline XBRL Instance Document 101.SCH Â Inline XBRL Taxonomy Extension Schema Document 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Filed herewith. # Indicates management contract or compensatory plan or arrangement. Â ++ This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing herewith. Â 23 Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â PROCESSA PHARMACEUTICALS, INC. Â Â Â By: /s/ George Ng Â George Ng Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Dated: August 13, 2024 Â Â Â By:Â /s/ Russell SkibstedÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Russell Skibsted Â Â Chief Financial Officer Â Â (Principal Financial and Accounting Officer) Â Â Dated: August 13, 2024 Â 24 EX-31.1 2 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION Â I, George Ng, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2024; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report; Â 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of registrantâ€™s board of directors (or persons performing equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â By: /s/ George Ng Â George Ng Â Chief Executive Officer (Principal Executive Officer) Â Date: August 13, 2024 Â EX-31.2 3 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION Â I, Russell Skibsted, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2024; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report; Â 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of registrantâ€™s board of directors (or persons performing equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â By: /s/ Russell Skibsted Â Â Russell Skibsted Â Â Chief Financial Officer (Principal Financial and Accounting Officer) Â Date: August 13, 2024 Â EX-32.1 4 ex32-1.htm Â Exhibit 32.1 Â Written Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Â§1350 Â Solely for the purposes of complying with 18 U.S.C. Â§1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc. (the â€œCompanyâ€), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â This certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â Â By: /s/ George Ng Â Â George Ng Â Â Chief Executive Officer (Principal Executive Officer) Â Date: August 13, 2024 Â Solely for the purposes of complying with 18 U.S.C. Â§1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc. (the â€œCompanyâ€), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â This certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â Â By: /s/ Russell Skibsted Â Â Russell Skibsted Â Â Chief Financial Officer (Principal Financial and Accounting Officer) Â Date: August 13, 2024 Â A Â GRAPHIC 5 form10-q_001.jpg begin 644 form10-q_001.jpg M_]C_X O2D:ng[...]

M_]C_X O2D:ng[...]
M_]C_4!]@0$)1045%! 0$!04%!@8&"!H;"0D)"@D9$ P:(!PD(R ?(R @)2D]
... (uuencoded binary image data) ...
ME7P7P\SODA6P6HL`E!"#/#/#/@%9\<'*\B]6#\F#&VL*@2/?+G?#QX'(!%RF^=C0`Q2T@Q*!1@R%@
ME%KHL/ATP0+L_C4L.3A$6U3``&=%>G(MCQE)N)8^0F]7]D)4#,BTU?:"@'J$|7_!6[Q=W_F^%%=[*[L$#;GFM^QV2S+*?4U%EA

'16:TWRT(1A.=!TX9A4C%0E5ITIX62AR8B:P|\/ M&J[$NMPQS^W>$RSVCQ,<5[=Y/A/:/%OF4,9[:65Q]2Q#C&4XXU5)5W37/'%. M.A^Q7Q2^!_@#XN?#CQ;*O$>GW&E^#_'=[;70BZU\)S0^&[S7GCUC3M9OX]0 MO;&W$LR:_)ID-CX@D(^U:IIDMU937(2=F'K$$$%K!#:VT4<%O;11P6\$2+'% M#!"BQQ11(H"I"&JHB* JJH K]Z_V!_P!NOQA^V3??%O1/'7[/=S|/$?P ML\-_L[^*[G1Y/B9IOQ,,UE^T3\]K7XN:'H.MW>G>%?"L?A_QIX7T"^T]3Q]H M"1ZO;P6NOZ%%F5+,L#4>4YA4FGA:LL3]7^L4\31A6QF'P
M_-7A4I5*M.I.MAZ&&@ZBJU/W=&G33A&"C+T,#@\I>(JYQ@<'A]*^$*QF$P7%7UL M93P_L*]?!?9B*=7PV#*DN6GR4R4,C,PS"O"E"1C]8Q>(KS]M5JI.I$HHHKS#U# MX9_X*&_#_##
[QQ\2/V>[+2?"'A#5OB?HFA_&/X(>-OB[\(M -L^N?%_X'>#/B9X M>)0_%7X#IFG77??LMQ^>&H> M/VDM$\#?M 'X6?!#XN6//@OQ]1_#?? 9ZUSE]C_XDCV@_4?!?B[5
M/&6H>.O#$GA,,X6_$GXP>,,>_ OPXUBS|)^!;?Q%X9^%MGXCOK[74$>5H6?2A#_$F MKP?[M7;%?7B?B[X"^!G@'6?
B7\2M9ET7PKHDHNE6(_$WB/Q#]>FZ#X>>]/Z+#87N]:OJ^*H6EC96TLTTRBO'"/#?[=/[. M^]Z;XLN_%_#Q/!\&-'+^^>>X?^$/CCX1U[X8^,-"U?XU:[%X:^$*$MS<:+ MK]HC76@^/];>?3]"|2Z;/?: L^EZ^FIZCI[>&]?&F_4Y5CL?1R^%.GDW]HX6 MCBY3C-X$N>N#]K3KX:M.#I4/VU15*5*"FJRNO$J*]BPU93BZ&'GB92ECO MJU6=&*'?%?A7M%0M3T?6]=TB#]?V:_A[^T
M=UW30#^^GKJ6;K^GJ^*+^NFO0'AVU'1=:BG/0HWEX^&(,?&?6C>%%-3C_M7PKJ'C&PN_2/!OC $;\ '")>|'S$+V'NQA=#X9&LC."PS"""EL"'XX.COF""C^C^$
M_UW30#+^[]/^[G1Y/B9IOQ,,UE^T3\]K7XN:'H.MW>G>

BBB@ HHHH ** "BBB@ HHHH **** "BBB@ HHJ"YCFE@DCM[AK29P EPL<O,XO@M\'(QM4N8/A-\,X;C6[/QSI^M3Q>_ M"T_L_B'JMC9:GXYMKMI8? %NH6=K>Z^FH7-O#*G M6_V9K/\ T,ES_P""S2_)'H_LS6?^ADN?\ P6:7-P#([7"I4IW]G4J4^:W~M[.I4I\W"]QYN2<.:SU7-S6>JL]291^W-&,K7MS1C*VU9VHRRM=:.UKK1W6A MRUE\'/A#IMS9WFG?"OX,V%WIVM:;XET^ZLO_ABUN;'Q'H_@W_A76D:_9SP: M7'+:ZUI7P^_XH73=5@9+ZQ\&_P#%,6L\6B?Z#7;:,9^S)^S;HOAF7P7'=_M/=25*K.DY5J<*],#U\10C4C6I-4<15PPM"56-O:>ZXTJ[&,YI\=? T,1*(G^)>L_%[28 M?A9X&^)>O_M:A:E\9E^(OA>WNQX]]\\++_!/6?V-%_9YD^NB^)8_#>FZA<<2:-XQ M$.LV'A-KC3.!M[I&F:=J<[VNL[Q1V=0\l /? P3_P""3GB[PA\(Y/AOX^TWX?ZO M?7_BO]BBQ^(MQJ7Q/UOQOYX*^,O@K]F3XV:=|2?&NNZQX"/P5^]AH/B+QOHZ MZS#Z}#VOB#;^}/B#5[C5Y/#7B[X@W>@650>S_N;_9FL_| 0R7/_@LTO_Y'L_LS M6?\ H9?G+P %FE__'7;#BO.H4G2C?@HMT&G[-\\5ADE1C&I[9S5.FHIPN M?)3FO.THTJSE5E@\GP,I<[I#;_>77,N5NK7G;C[/EYI7?>}+FDGRS|/2_++_,8OV?
X=+XI_9AU3QSING?'WQG>:AX|>*?AK\!?MJ>"=?\:1X@\+/&?%,_@77_#HT0PWJG&&^M_".LZ3]DW4O#5W8V=EK7}HV'MRR\ /\ 8W:Z^:/O[3'P ^=GB^_9Z\/^_AOXO_&*/
{!IGA%=$\??!+P]I]^_B>R\4 M^^%]>T57WEE_6[^S-9 Z&2Y_\%FE_(]'F:S_P!#)<^^S2_D>N7'9(C<$] M3I0O17Z{#3P9\$<#N"7*'R_/5|\-&[X7ZM%?:Z]
M^A'7Y===BR+T=S2-&T_PYI-H-Y*#&EV^14XM*2B 9U~+48R5W^+5_P#?|\ $L|/ LTS C^J|$L/& MT/PYPU7P_X_(_)> O'GC/X2_MM^^/X^;]/B9XRY/VU3EE_/K>D?]v_ &+&^&]5L7-M@^-$^% M4~^A7Y'==U8QJ5;^93M_I>6^0@3+/(_>15S_ 2N==(?..^=.G4YK^JT;.+=9_>KZ~_M_\MS^=>T^\_V:}#?ROVLD/I/2DT+/*L|_/|+-M.=-E%=RLV7;P_^D(>/^X_C>_?%,J8^~;?>?T[=?S|/$U/><<X!X/$$T_?{^[%
{X[7Z Z_7Q_ M^\%K;Y>,Z K=3T[.J> @L \|A# M M]?P:_-
^1TZKOL_-+=}M@^_"VB^*-0[):;#/##?6$6Z'8V.MWGA6GGZZ[{LDHT#]T#P_=Z=^;B6'3}6CFBDE$/XN(D=6D@ M;}[.C65 >8S)' LB!NA&&##L0:VJ "BBB@ HHHH **** M "BBB@ HHHH ****M "BBB@ HHHH **** "BBB@ HHHH ****M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB $B@#_V0$! end EX-101.SCH 6 pcsa-20240630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Net Loss per Share of Common Stock link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Net Loss per Share of Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Schedule of Restricted Stock Units ("RSUs") Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pcsa-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pcsa-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pcsa-20240630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock, Common [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Consulting Agreement [Member] Legal Entity [Axis] Spartan Capital Securites LLC [Member] Purchase Agreement [Member] Class of Warrant or Right [Axis] Pre-Funded Warrants [Member] Warrant [Member] Sales Agreement [Member] Related and Nonrelated Parties [Axis] Alliance Global Partners [Member] Statistical Measurement [Axis] Maximum [Member] Sale of Stock [Axis] ATM Offering [Member] Placement Agent [Member] Elion Oncology, Inc. [Member] License Agreement [Member] Consultant [Member] Employees and Consultants [Member] Plan Name [Axis] 2019 Plan [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Title and Position [Axis] Employees [Member] Service Based RSUs [Member] Vesting [Axis] January 1, 2025 Vesting [Member] Title Of Inidividual [Axis] 3-Year Vesting [Member] First Performance Based RSUs [Member] Second Performance Based RSUs [Member] Next Generation Capecitabine - Cap [Member] Offering [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Antidilutive Securities [Axis] Long-Lived Tangible Asset [Axis] Facility Lease [Member] Equipment [Member] Related Party Transaction [Axis] CorLyst, LLC [Member] CROs [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Service Based RSU [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Prepaid expenses and other Total Current Assets Property and Equipment, net Other Assets Lease right-of-use assets, net of accumulated amortization Security deposit Total Other Assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Current maturities of lease liabilities Accounts payable Due to licensor Due to related parties Accrued expenses Total Current Liabilities Non-current Liabilities Non-current lease liabilities Total Liabilities Commitments and Contingencies Stockholders' Equity Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023 Additional paid-in capital Treasury stock at cost — 5,000 shares at June 30, 2024 and December 31, 2023 Accumulated deficit Total Stockholders' Equity Total Liabilities and Stockholders' Equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury Stock shares Income Statement [Abstract] Operating Expenses Research and development expenses General and administrative expenses Operating Loss Other Income (Expense), net Net Operating Loss Before Income Tax Benefit Income Tax Benefit Net Loss Net Loss per Common Share - Basic Net Loss per Common Share - Diluted Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Stock-based compensation Stock-based compensation, shares Shares issued in connection with capital raise, net of transaction costs Shares issued in connection with capital raise, net of transaction costs, shares Net loss Warrants issued in connection with a consulting agreement Shares issued in

Cover - shares	6 Months Ended	
	Jun. 30, 2024	Aug. 01, 2024

Cover [Abstract]

Document Type	10-Q	
Amendment Flag	false	
Document Quarterly Report	true	
Document Transition Report	false	
Document Period End Date	Jun. 30, 2024	
Document Fiscal Period Focus	Q2	
Document Fiscal Year Focus	2024	
Current Fiscal Year End Date	--12-31	
Entity File Number	001-39531	
Entity Registrant Name	Processa Pharmaceuticals, Inc.	
Entity Central Index Key	0001533743	
Entity Tax Identification Number	45-1539785	

Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7380 Coca Cola Drive
Entity Address, Address Line Two	Suite 106
Entity Address, City or Town	Hanover
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21076
City Area Code	443
Local Phone Number	776-3133
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	PCSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	3,256,944

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets		
Cash and cash equivalents	$ 5,571,120	$ 4,706,197
Prepaid expenses and other	1,906,854	926,300
Total Current Assets	7,477,974	5,632,497
Property and Equipment, net	2,276	2,554
Other Assets		
Lease right-of-use assets, net of accumulated amortization	115,191	146,057
Security deposit	5,535	5,535
Total Other Assets	120,726	151,592
Total Assets	7,600,976	5,786,643
Current Liabilities		
Current maturities of lease liabilities	93,181	83,649
Accounts payable	953,086	311,617
Due to licensor		189,000
Due to related parties		39
Accrued expenses	505,397	146,274
Total Current Liabilities	1,551,664	730,579
Non-current Liabilities		
Non-current lease liabilities	25,648	66,905
Total Liabilities	1,577,312	797,484
Commitments and Contingencies		
Stockholders' Equity		
Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023	287	129
Additional paid-in capital	87,429,165	80,658,111
Treasury stock at cost — 5,000 shares at June 30, 2024 and December 31, 2023	(300,000)	(300,000)
Accumulated deficit	(81,105,788)	(75,369,081)
Total Stockholders' Equity	6,023,664	4,989,159
Total Liabilities and Stockholders' Equity	$ 7,600,976	$ 5,786,643

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,873,883	1,291,000
Common stock, shares outstanding	2,868,883	1,286,000
Treasury stock shares	5,000	5,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating Expenses				
Research and development expenses	$ 1,730,444	$ 1,688,164	$ 3,269,555	$ 3,342,509
General and administrative expenses	1,351,580	1,026,301	2,622,067	3,477,490
Operating Loss	(3,082,024)	(2,714,465)	(5,891,622)	(6,819,999)
Other Income (Expense), net	71,698	101,900	154,915	185,361
Net Operating Loss Before Income Tax Benefit	(3,010,326)	(2,612,565)	(5,736,707)	(6,634,638)
Income Tax Benefit				
Net Loss	$ (3,010,326)	$ (2,612,565)	$ (5,736,707)	$ (6,634,638)
Net Loss per Common Share - Basic	$ (1.01)	$ (1.94)	$ (2.11)	$ (5.34)
Net Loss per Common Share - Diluted	$ (1.01)	$ (1.94)	$ (2.11)	$ (5.34)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic	2,983,283	1,346,808	2,724,903	1,243,475
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted	2,983,283	1,346,808	2,724,903	1,243,475

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 80	$ 72,018,222	$ (300,000)	$ (64,247,561)	$ 7,470,741
Balance, shares at Dec. 31, 2022	806,774		(5,000)		
Stock-based compensation	$ 1	341,503			341,504
Stock-based compensation, shares	3,195				
Shares issued in connection with capital raise, net of transaction costs	$ 42	6,352,035			6,352,077
Shares issued in connection with capital raise, net of transaction costs, shares	421,611				
Net loss				(4,022,073)	(4,022,073)
Balance at Mar. 31, 2023	$ 123	78,711,760	$ (300,000)	(68,269,634)	10,142,249
Balance, shares at Mar. 31, 2023	1,231,580		(5,000)		

Balance at Dec. 31, 2022	$ 80	72,018,222	$ (300,000)	(64,247,561)	7,470,741
Balance, shares at Dec. 31, 2022	806,774		(5,000)		
Net loss					(6,634,638)
Balance at Jun. 30, 2023	$ 123	80,341,758	$ (300,000)	(70,882,199)	9,159,682
Balance, shares at Jun. 30, 2023	1,231,580		(5,000)		
Balance at Mar. 31, 2023	$ 123	78,711,760	$ (300,000)	(68,269,634)	10,142,249
Balance, shares at Mar. 31, 2023	1,231,580		(5,000)		
Stock-based compensation		319,123			319,123
Net loss				(2,612,565)	(2,612,565)
Warrants issued in connection with a consulting agreement		1,310,875			1,310,875
Balance at Jun. 30, 2023	$ 123	80,341,758	$ (300,000)	(70,882,199)	9,159,682
Balance, shares at Jun. 30, 2023	1,231,580		(5,000)		
Balance at Dec. 31, 2023	$ 129	80,658,111	$ (300,000)	(75,369,081)	4,989,159
Balance, shares at Dec. 31, 2023	1,291,000		(5,000)		
Stock-based compensation	$ 1	167,642			167,643
Stock-based compensation, shares	13,176				
Shares issued in connection with capital raise, net of transaction costs	$ 156	6,282,274			6,282,430
Shares issued in connection with capital raise, net of transaction costs, shares	1,555,555				
Net loss				(2,726,381)	(2,726,381)
Shares issued in connection with license agreement	$ 1	188,999			189,000
Shares issued in connection with license agreement, shares	5,000				
Settlement of stock award		(8,561)			(8,561)
Shares withheld to pay income taxes on stock-based compensation	$ (1)	(9,923)			(9,924)
Shares withheld to pay income taxes on stock-based compensation, shares	(3,750)				
Balance at Mar. 31, 2024	$ 286	87,278,542	$ (300,000)	(78,095,462)	8,883,366
Balance, shares at Mar. 31, 2024	2,860,981		(5,000)		
Balance at Dec. 31, 2023	$ 129	80,658,111	$ (300,000)	(75,369,081)	4,989,159
Balance, shares at Dec. 31, 2023	1,291,000		(5,000)		
Net loss					(5,736,707)
Balance at Jun. 30, 2024	$ 287	87,429,165	$ (300,000)	(81,105,788)	6,023,664
Balance, shares at Jun. 30, 2024	2,873,883		(5,000)		
Balance at Mar. 31, 2024	$ 286	87,278,542	$ (300,000)	(78,095,462)	8,883,366
Balance, shares at Mar. 31, 2024	2,860,981		(5,000)		
Stock-based compensation	$ 1	152,631			152,632
Stock-based compensation, shares	14,167				
Net loss				(3,010,326)	(3,010,326)
Shares withheld to pay income taxes on stock-based compensation		(2,008)			(2,008)
Shares withheld to pay income taxes on stock-based compensation, shares	(1,265)				
Balance at Jun. 30, 2024	$ 287	$ 87,429,165	$ (300,000)	$ (81,105,788)	$ 6,023,664
Balance, shares at Jun. 30, 2024	2,873,883		(5,000)		

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows From Operating Activities		
Net loss	$ (5,736,707)	$ (6,634,638)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	278	
Non-cash lease expense for right-of-use assets	42,670	39,982
Stock-based compensation	320,275	660,627
Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreement		1,310,875
Net changes in operating assets and liabilities:		
Prepaid expenses and other	(980,554)	662,984
Operating lease liability	(41,228)	(38,233)
Accounts payable	641,469	(88,526)
Due to related parties	(39)	(51)
Accrued expenses	359,123	(91,559)
Net cash used in operating activities	(5,394,713)	(4,178,539)
Cash Flows From Financing Activities		
Net proceeds from issuance of stock	6,282,430	6,352,077
Shares withheld to pay taxes on stock-based compensation	(11,932)	
Settlement of stock award	(8,561)	
Payment of finance lease obligation	(2,301)	
Net cash provided by financing activities	6,259,636	6,352,077
Net Increase in Cash	864,923	2,173,538
Cash and Cash Equivalents – Beginning of Period	4,706,197	6,503,595
Cash and Cash Equivalents – End of Period	5,571,120	8,677,133
Non-Cash Financing Activities		
Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor	189,000	
Right-of-use asset	11,804	
Financing lease liability	(11,804)	
Net		

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - shares	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Common Stock [Member]		
Shares issued in connection with license agreement	5,000	
Consulting Agreement [Member] | Spartan Capital Securites LLC [Member]		
Warrants to purchase shares		158,007

XML 19 R8.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)	3 Months Ended			6 Months Ended		
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]						
Net Income (Loss)	$ (3,010,326)	$ (2,726,381)	$ (2,612,565)	$ (4,022,073)	$ (5,736,707)	$ (6,634,638)

XML 20 R9.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]	

XML 21 R10.htm IDEA: XBRL DOCUMENT

| Organization and Summary of Significant Accounting Policies | 6 Months Ended Jun. 30, 2024 |

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy ("NGC") drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.

On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split of our common stock, par value $0.0001 per share (the "Reverse Stock Split"). Pursuant to the Certificate of Amendment, our issued common stock decreased from 24,706,474 shares to 1,291,000 shares and our outstanding common stock decreased from 24,606,474 to 1,286,000. The Reverse Stock Split did not affect our authorized common stock of 100,000,000 shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions of the Securities and Exchange Commission ("SEC") on Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Liquidity

Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.

We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock.

In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.

At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business plans, we believe these funds will satisfy our operating needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management's experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, *Income Taxes*. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal.

Under ACS 740-270 *Income Taxes – Interim Reporting*, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation ("FDIC") up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.

Recent Accounting Pronouncements

From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update ("ASU"). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

XML 22 R11.htm IDEA: XBRL DOCUMENT

| Stockholders' Equity | 6 Months Ended Jun. 30, 2024 |

Equity [Abstract]

Stockholders' Equity

Note 2 – Stockholders' Equity

Preferred Stock

There were no issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023.

Common Stock

During the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the "Pre-Funded Warrants"), and warrants to purchase up to 1,555,555 shares of our common stock (the "Common Warrants') in a public offering (the "Offering"). The Common Warrants have an exercise price of $4.50, are immediately exercisable and expire on January 30, 2029. The shares of common stock were offered at a combined public offering price of $4.50 per share and accompanying Common Warrant and $4.4999 per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $0.0001 and were exercised in full simultaneously with the closing of the Offering in exchange for 1,079,555 shares of our common stock. Gross proceeds in connection with the Offering were $7.0 million. We received $6.3 million in net proceeds from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement agent warrants to purchase 62,222 shares of common stock, exercisable at $5.625 per share that expire on February 1, 2027.

During the six months ended June 30, 2024, we also issued: 5,000 shares of common stock to Elion Oncology, Inc. ("Elion") in satisfaction of the third milestone event under the license agreement;

10,000 shares of common stock to a consultant in accordance with their consulting agreement; and 12,328 shares of common stock to certain employees and consultants, net of 5,015 shares of common stock withheld for income taxes owed upon distribution of the shares.

Stock-based Compensation	6 Months Ended Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

Note 3 - Stock-based Compensation

On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of 800,000 shares of our common stock. At June 30, 2024, we have 503,129 shares available for future grants.

Stock Compensation Expense

We recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:

	Three Months Ended June 30,				Six Months Ended June 30,			
	2024		2023		2024		2023	
Research and development	$	45,583	$	102,678	$	76,704	$	209,526
General and administrative		107,049		216,445		243,571		451,101
Total	$	152,632	$	319,123	$	320,275	$	660,627

Stock Options

Stock options to purchase 4,245 shares of common stock with a weighted-average exercise price of $336.00 expired during the six months ended June 30, 2024. At June 30, 2024, we had outstanding and exercisable options for the purchase of 2,747 shares with a weighted average exercise price of $409.09 and a weighted average remaining contractual life of 4.2 years. At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock options.

Restricted Stock Awards

During the six months ended June 30, 2024, we vested 1,250 Restricted Stock Awards ("RSAs") with a weighted average grant-date fair value of $9.26 per share. We had no RSAs outstanding at June 30, 2024.

Restricted Stock Units

Activity with respect to our Restricted Stock Units ("RSUs") during the six months ended June 30, 2024 was as follows:

	Number of shares		Weighted- average grant-date fair value per share
Outstanding at January 1, 2024	222,722	$	45.82
Granted	39,202		2.24
Forfeited	(10,775)		58.37
Issued	(12,328)		99.86
Outstanding at June 30, 2024	238,821		35.31
Vested and unissued	143,793		50.71
Unvested at June 30, 2024	95,028	$	12.00

On June 28, 2024, we granted RSUs for the future issuance of 39,202 shares of common stock to our employees which vest accordingly: RSUs for the future issuance of 14,969 shares of common stock vest on January 1, 2025; RSUs for the future issuance of 18,173 shares of common stock vest over a three-year period upon meeting service requirements; RSUs for the future issuance of 3,030 shares of common stock vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of 3,030 shares of common stock vest upon dosing the first patient in our Phase 2 study in NGC-Cap.

At June 30, 2024, unrecognized stock-based compensation expense of approximately $538,000 for RSUs is expected to be fully recognized over a weighted average period of 1.7 years. The unrecognized expense excludes approximately $420,000 of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.

Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.

Warrants

During the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase 1,617,777 shares of common stock as part of the Offering (see Note 2). Warrants to purchase 5,000 shares of our common stock expired unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of 15,000 shares of our common stock in exchange for a payment of $10,000.

At June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of 1,778,284 shares with a weighted average exercise price of $6.17 and a weighted average remaining contractual life of 4.3 years. All the outstanding stock purchase warrants are exercisable as of June 30, 2024. We did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2024.

Net Loss per Share of Common Stock	6 Months Ended Jun. 30, 2024

Earnings Per Share [Abstract]

Net Loss per Share of Common Stock

Note 4 – Net Loss per Share of Common Stock

Net Loss Per Share

Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share.

The computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,			
	2024		2023		2024		2023	
Basic and diluted net loss per share:								
Net loss available to common stockholders	$	(3,010,326)	$	(2,612,565)	$	(5,736,707)	$	(6,634,638)
Weighted average number of common shares-basic and diluted		2,983,283		1,346,808		2,724,903		1,243,475
Basic and diluted net loss per share	$	(1.01)	$	(1.94)	$	(2.11)	$	(5.34)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Weighted-average number of common shares outstanding – basic and diluted	2,849,192	1,217,095	2,590,530	1,114,324
Weighted-average number of vested RSUs– basic and diluted	134,091	129,713	134,373	129,151
Weighted-average number of common shares-basic and diluted	2,983,283	1,346,808	2,724,903	1,243,475

Our diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded 1,876,059 and 254,314 of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.

Leases	6 Months Ended Jun. 30, 2024

Leases

Leases

Note 5 – Leases

We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% in determining the present value of the lease payments based on the information available at the lease commencement date.

Lease costs included in our condensed consolidated statements of operations totaled approximately $23,000 and $24,000 for the three months ending June 30, 2024 and 2023, respectively, and approximately $45,000 and $49,000 for the six months ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as follows at June 30, 2024:

Remaining lease term (years) for our facility lease	1.3
Remaining lease term (years) for our equipment lease	1.6
Weighted average discount rate for our facility and equipment leases	8.0%

Annual lease liabilities for the operating lease were as follows at June 30, 2024:

2024	$	45,797
2025		70,040
Total lease payments		115,837
Less: Interest		(6,511)
Present value of lease liabilities		109,326
Less: current maturities		(87,495)
Non-current lease liability	$	21,831

Annual lease liabilities for the financing lease were as follows at June 30, 2024:

2024	$	3,232
2025		6,820
2026		488
Total lease payments		10,540
Less: Interest		(1,037)
Present value of lease liabilities		9,503
Less: current maturities		(5,686)
Non-current lease liability	$	3,817

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions	**6 Months Ended**
	Jun. 30, 2024

Related Party Transactions [Abstract]

Related Party Transactions

Note 6 – Related Party Transactions

CorLyst, LLC ("CorLyst") reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded approximately $27,000 and $34,000 of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $50,000 and $64,000 for the six months ended June 30, 2024 and 2023, respectively. No amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst is a shareholder.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	**6 Months Ended**
	Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7 – Commitments and Contingencies

Purchase Obligations

We enter into contracts in the normal course of business with contract research organizations ("CROs") and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $14.3 million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining clinical trials.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Event	**6 Months Ended**
	Jun. 30, 2024

Subsequent Events [Abstract]

Subsequent Event

Note 8 – Subsequent Event

On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). Mr. Skibsted has nearly 30 years of experience in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target bonus of 35% of his base compensation. In addition, the Compensation Committee awarded 28,000 RSUs to Mr. Skibsted, which vest accordingly: 14,000 RSUs vest on July 16, 2025; 7,000 RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa's outstanding shares of stock at the then current market price) of at least $30 million; and 7,000 RSUs vest upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment agreement.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	**6 Months Ended**
	Jun. 30, 2024

Accounting Policies [Abstract]

Organization

Organization

We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy ("NGC") drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.

On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split of our common stock, par value $0.0001 per share (the "Reverse Stock Split"). Pursuant to the Certificate of Amendment, our issued common stock decreased from 24,706,474 shares to 1,291,000 shares and our outstanding common stock decreased from 24,606,474 to 1,286,000. The Reverse Stock Split did not affect our authorized common stock of 100,000,000 shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split.

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions of the Securities and Exchange Commission ("SEC") on Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Liquidity

Liquidity

Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.

We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock.

In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.

At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business plans, we believe these funds will satisfy our operating needs into late 2024, including the

beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

Use of Estimates

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management's experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Income Taxes

Income Taxes

We account for income taxes in accordance with ASC Topic 740, *Income Taxes*. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal.

Under ACS 740-270 *Income Taxes – Interim Reporting*, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation ("FDIC") up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update ("ASU"). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)	6 Months Ended Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

We recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:

	Three Months Ended June 30,				Six Months Ended June 30,			
		2024		2023		2024		2023
Research and development	$	45,583	$	102,678	$	76,704	$	209,526
General and administrative		107,049		216,445		243,571		451,101
Total	$	152,632	$	319,123	$	320,275	$	660,627

Schedule of Restricted Stock Units ("RSUs") Activity

Activity with respect to our Restricted Stock Units ("RSUs") during the six months ended June 30, 2024 was as follows:

	Number of shares		Weighted- average grant-date fair value per share
Outstanding at January 1, 2024	222,722	$	45.82
Granted	39,202		2.24
Forfeited	(10,775)		58.37
Issued	(12,328)		99.86
Outstanding at June 30, 2024	238,821		35.31
Vested and unissued	143,793		50.71
Unvested at June 30, 2024	95,028	$	12.00

XML 31 R20.htm IDEA: XBRL DOCUMENT

Net Loss per Share of Common Stock (Tables)	6 Months Ended Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of Net Loss Per Share Basic and Diluted

The computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,			
		2024		2023		2024		2023
Basic and diluted net loss per share:								
Net loss available to common stockholders	$	(3,010,326)	$	(2,612,565)	$	(5,736,707)	$	(6,634,638)
Weighted average number of common shares- basic and diluted		2,983,283		1,346,808		2,724,903		1,243,475
Basic and diluted net loss per share	$	(1.01)	$	(1.94)	$	(2.11)	$	(5.34)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Weighted-average number of common shares outstanding – basic and diluted	2,849,192	1,217,095	2,590,530	1,114,324
Weighted-average number of vested RSUs– basic and diluted	134,091	129,713	134,373	129,151
Weighted-average number of common shares- basic and diluted	2,983,283	1,346,808	2,724,903	1,243,475

XML 32 R21.htm IDEA: XBRL DOCUMENT

Leases (Tables)	6 Months Ended Jun. 30, 2024

Leases

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases

Remaining lease term (years) for our facility lease	1.3
Remaining lease term (years) for our equipment lease	1.6
Weighted average discount rate for our facility and equipment leases	8.0%

Schedule of Annual Lease Liabilities for all Operating Leases

Annual lease liabilities for the operating lease were as follows at June 30, 2024:

2024	$	45,797
2025		70,040
Total lease payments		115,837
Less: Interest		(6,511)
Present value of lease liabilities		109,326
Less: current maturities		(87,495)
Non-current lease liability	$	21,831

Schedule of Annual Lease Liabilities for all Financing Leases

Annual lease liabilities for the financing lease were as follows at June 30, 2024:

2024	$	3,232
2025		6,820
2026		488

Total lease payments	10,540
Less: Interest	(1,037)
Present value of lease liabilities	9,503
Less: current maturities	(5,686)
Non-current lease liability	$ 3,817

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)

	May 31, 2024	May 21, 2024	Jan. 30, 2024	Jan. 22, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jan. 21, 2024	Dec. 31, 2023
					3 Months Ended				**6 Months Ended**			
OrganizationLineItems [Line Items]												
Reverse stock split				1-for-20 reverse stock split								
Common stock, par value				$ 0.0001	$ 0.0001				$ 0.0001			$ 0.0001
Common stock shares issued				1,291,000	2,873,883				2,873,883		24,706,474	1,291,000
Common stock shares outstanding				1,286,000	2,868,883				2,868,883		24,606,474	1,286,000
Common stock shares authorized				100,000,000	100,000,000				100,000,000			100,000,000
Accumulated deficit					$ 81,105,788				$ 81,105,788			$ 75,369,081
Net loss					3,010,326	$ 2,726,381	$ 2,612,565	$ 4,022,073	5,736,707	$ 6,634,638		
Net cash for operating activities from continuing operations									5,394,713	4,178,539		
Net proceeds			$ 6,300,000						6,282,430	$ 6,352,077		
Shares issued initial offering	$ 50,000,000				$ 6,282,430			$ 6,352,077				
Cash and cash equivalents					$ 5,571,120				$ 5,571,120			$ 4,706,197
Purchase Agreement [Member]												
OrganizationLineItems [Line Items]												
Number of shares sold			476,000						476,000			
Net proceeds									$ 6,300,000			
**Purchase Agreement [Member]	Warrant [Member]**												
OrganizationLineItems [Line Items]												
Warrants to purchase shares			1,555,555		1,555,555				1,555,555			
**Purchase Agreement [Member]	Pre-Funded Warrants [Member]**												
OrganizationLineItems [Line Items]												
Warrants to purchase shares			1,079,555		1,079,555				1,079,555			
Warrant exercised			1,079,555		1,079,555				1,079,555			
**Sales Agreement [Member]	Alliance Global Partners [Member]	Maximum [Member]	ATM Offering [Member]**												
OrganizationLineItems [Line Items]												
Maximum value to be sold at the market offering		$ 2,400,000										

Stockholders' Equity (Details Narrative) - USD ($)

	Jan. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
		6 Months Ended		
Class of Stock [Line Items]				
Preferred stock, shares issued		0	0	
Preferred stock, shares outstanding		0	0	
Proceeds from Issuance of Common Stock	$ 6,300,000	$ 6,282,430	$ 6,352,077	
Stock withheld for income taxes		5,015		
Employees and Consultants [Member]				
Class of Stock [Line Items]				
Shares issued		12,328		
Purchase Agreement [Member]				
Class of Stock [Line Items]				
Shares issued	476,000	476,000		
Gross proceeds from issuance of common stock		$ 7,000,000.0		
Proceeds from Issuance of Common Stock		$ 6,300,000		
**Purchase Agreement [Member]	Placement Agent [Member]**				
Class of Stock [Line Items]				
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.625		
Class of Warrant or Right, Outstanding		62,222		
Warrants and Rights Outstanding, Maturity Date		Feb. 01, 2027		
**Purchase Agreement [Member]	Warrant [Member]**				
Class of Stock [Line Items]				
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,555,555	1,555,555		
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.50		
Warrants exercisable and maturity date		Jan. 30, 2029		
**Purchase Agreement [Member]	Pre-Funded Warrants [Member]**				
Class of Stock [Line Items]				
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,079,555	1,079,555		
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0001		
Shares Issued, Price Per Share		$ 4.4999		
[custom:StockIssuedDuringPeriodSharesWarrantExercised-0]	1,079,555	1,079,555		
**License Agreement [Member]	Elion Oncology, Inc. [Member]**				
Class of Stock [Line Items]				
Shares issued		5,000		
**Consulting Agreement [Member]	Consultant [Member]**				
Class of Stock [Line Items]				
Shares issued		10,000		

Schedule of Stock-based Compensation Expense (Details) - USD ($)

	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
	3 Months Ended		**6 Months Ended**	
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]				
Total	$ 152,632	$ 319,123	$ 320,275	$ 660,627
Research and Development Expense [Member]				
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]				
Total	45,583	102,678	76,704	209,526
General and Administrative Expense [Member]				
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]				
Total	$ 107,049	$ 216,445	$ 243,571	$ 451,101

Schedule of Restricted Stock Units ("RSUs") Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended Jun. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Number of shares, Beginning balance	shares	222,722
Weighted-average grant-date fair value per share, Beginning balance	$ / shares	$ 45.82
Number of shares, granted	shares	39,202
Weighted-average grant-date fair value per share, granted	$ / shares	$ 2.24
Number of shares, forfeited	shares	(10,775)
Weighted-average grant-date fair value per share, forfeited	$ / shares	$ 58.37
Number of shares, issued	shares	(12,328)
Weighted-average grant-date fair value per share, shares issued	$ / shares	$ 99.86
Number of shares, ending balance	shares	238,821
Weighted-average grant-date fair value per share, ending balance	$ / shares	$ 35.31
Number of shares, vested and unissued	shares	143,793
Weighted-average grant-date fair value per share, vested and unissued	$ / shares	$ 50.71
Number of shares, unvested	shares	95,028
Weighted-average grant-date fair value per share, unvested	$ / shares	$ 12.00

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Details Narrative) - USD ($)	Jun. 28, 2024	6 Months Ended Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Payments for settlement of stock awards		$ 8,561		
Warrant [Member]	Offering [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Warrants to purchase shares		1,617,777		
Consulting Agreement [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Warrants, expired		5,000		
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures		15,000		
Payments for settlement of stock awards		$ 10,000		
Share-Based Payment Arrangement, Option [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Options, forfeited		4,245		
Options, forfeited weighted average exercise price		$ 336.00		
Options exercisable, shares		2,747		
Options exercisable weighted average exercise price		$ 409.09		
Exercisable weighted average remaining contractual term		4 years 2 months 12 days		
Restricted Stock [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, vested		1,250		
Weighted-average grant-date fair value per share, shares vested		$ 9.26		
Number of shares, outstanding		0		
Restricted Stock Units (RSUs) [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, outstanding		238,821		222,722
Number of shares, granted		39,202		
Unrecognized share based compensation expense		$ 538,000		
Weighted average period for recognition		1 year 8 months 12 days		
Unrecognized share based compensation expense.		$ 420,000		
Restricted Stock Units (RSUs) [Member]	Employees [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, granted	39,202			
Service Based RSUs [Member]	3-Year Vesting [Member]	Employees [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, granted	18,173			
Service Based RSUs [Member]	Employees [Member]	January 1, 2025 Vesting [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, granted	14,969			
First Performance Based RSUs [Member]	Employees [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, granted	3,030			
Second Performance Based RSUs [Member]	Employees [Member]	Next Generation Capecitabine - Cap [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Number of shares, granted	3,030			
Warrant [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Warrants to purchase shares		1,778,284		
Weighted average exercise price		$ 6.17		
Weighted average remaining contractual life		4 years 3 months 18 days		
2019 Plan [Member]				
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]				
Maximum equity available for issuance	800,000			
Shares available for future grants		503,129		

XML 38 R27.htm IDEA: XBRL DOCUMENT

Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended Jun. 30, 2024	Jun. 30, 2023	6 Months Ended Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]				
Net loss available to common stockholders	$ (3,010,326)	$ (2,612,565)	$ (5,736,707)	$ (6,634,638)
Weighted average number of common shares-basic	2,983,283	1,346,808	2,724,903	1,243,475
Weighted average number of common shares-diluted	2,983,283	1,346,808	2,724,903	1,243,475
Basic net loss per share	$ (1.01)	$ (1.94)	$ (2.11)	$ (5.34)
Diluted net loss per share	$ (1.01)	$ (1.94)	$ (2.11)	$ (5.34)
Restricted Stock Units (RSUs) [Member]				
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]				
Weighted average number of common shares-basic	134,091	129,713	134,373	129,151
Weighted average number of common shares-diluted	134,091	129,713	134,373	129,151
Common Stock [Member]				
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]				
Weighted average number of common shares-basic	2,849,192	1,217,095	2,590,530	1,114,324
Weighted average number of common shares-diluted	2,849,192	1,217,095	2,590,530	1,114,324

XML 39 R28.htm IDEA: XBRL DOCUMENT

Net Loss per Share of Common Stock (Details Narrative) - shares	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Earnings Per Share [Abstract]

Antidilutive securities excluded from computation of earnings per share, amount	1,876,059	254,314	1,876,059	254,314

XML 40 R29.htm IDEA: XBRL DOCUMENT

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)	Jun. 30, 2024

Property, Plant and Equipment [Line Items]

Weighted average discount rate for our facility and equipment leases	8.00%

Facility Lease [Member]

Property, Plant and Equipment [Line Items]

Remaining lease term (years)	1 year 3 months 18 days

Equipment [Member]

Property, Plant and Equipment [Line Items]

Remaining lease term (years)	1 year 7 months 6 days

XML 41 R30.htm IDEA: XBRL DOCUMENT

Schedule of Annual Lease Liabilities for all Operating Leases (Details)	Jun. 30, 2024 USD ($)

Leases

2024	$ 45,797
2025	70,040
Total lease payments	115,837
Less: Interest	(6,511)
Present value of lease liabilities	109,326
Less: current maturities	(87,495)
Non-current lease liability	$ 21,831

XML 42 R31.htm IDEA: XBRL DOCUMENT

Schedule of Annual Lease Liabilities for all Financing Leases (Details)	Jun. 30, 2024 USD ($)

Leases

2024	$ 3,232
2025	6,820
2026	488
Total lease payments	10,540
Less: Interest	(1,037)
Present value of lease liabilities	9,503
Less: current maturities	(5,686)
Non-current lease liability	$ 3,817

XML 43 R32.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Leases

Operating and financing lease borrowing rate	8.00%		8.00%	
Lease cost	$ 23,000	$ 24,000	$ 45,000	$ 49,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Related Party Transaction [Line Items]

Rent and other costs reimbursements received	$ 27,000	$ 34,000	$ 50,000	$ 64,000
Due from related parties	$ 0	$ 0	$ 0	$ 0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) $ in Millions	Jun. 30, 2024 USD ($)

CROs [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Purchase obligation	$ 14.3

XML 46 R35.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details Narrative) - USD ($)	6 Months Ended	
	Jul. 16, 2024	Jun. 30, 2024

Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Number of shares, granted		39,202

Subsequent Event [Member]

Subsequent Event [Line Items]

Annual base salary	$ 400,000	
Potential base salary increase	50,000	
Potential base salary increase financing minimum	$ 15,000,000	
Executive bonus percentage	35.00%	

Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Number of shares, granted	28,000	

Subsequent Event [Member] | Service Based RSU [Member]

Subsequent Event [Line Items]

Number of shares, granted	14,000	

Subsequent Event [Member] | First Performance Based RSUs [Member]

Subsequent Event [Line Items]

Number of shares, granted	7,000	
Market capitalization	$ 30,000,000	

Subsequent Event [Member] | Second Performance Based RSUs [Member]

Subsequent Event [Line Items]

Number of shares, granted	7,000	
Performance vesting criteria	$ 15,000,000	

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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`Q.!='AR)S!E.3NN8J5:/]V@Q+'$4DF3E-I3$W5<-[]C\FZ<?.6C3[HK?!8_*)$$6!8OC#6ZM;^-5$U:1!%$;<K;+(;LI\GU(ICV<$?@G43\0F;=4"NI9EMJW$N2+PN,*/=JF*2,!!W,(HF3[ILY;W?LY+\NY3;5CM@&R)].GS;EUO\F+9X8_;G@Q?\WC[WH?(EHO\N?Z2EW96*!@!8BKKGF:YFNU]\N\+X/>1:R7FLWRQ/R@NL!+3?-?CL<</(W\88CITSZ\'EV;=%J@;SQ\IJ&U_*4H4ZQN/BD7@_<FXJK>?@*U#L!<Z\N:Q/GI^!-.&Y3[6+!:O;_B^0?S^D\OX\6S[3=BL7.V8[;7G,9_</J`9Q_@TQ";?V72[M=W,9&%F'F"*.#E\D`[3%_S=1.\BD<0Q\?EU8J+&7PAY')%$6Z9:)\s2HHT:;MB,;(TN/N5;/K+*\9=J$)W`==1XD"(/^\RZK!FU)U?[)]T-J=$_@'5\Z5;ZQLHOM?"YUI?9;YB%0E\.0MO]Y&&^%)\\FZ,.9IR<M\9G\[.!C*&\\Z`

B.!)K48\JZI';\AVY)'-]Q5A&DOPNB"1)]%V\"[?0 M *K1^83U5K!8@UU9$@%Q7(A15DQI4>.-IF091%VMA(Z(*ZV+M^!AU;UJQ' M,H5!?
6<,_@<56E)&6$39RM@"FF9I%V>9HCEZ84ZZQVIOS+&P#1L26F'OGB'* MC-M "\XRB38@(DVOG60G5FEJ@@97<-8;O&:RYCR6"==,^+CY%/V#CO<-]J2' MSC^NU-
I=5+NGL.=V\@V=VB97:FWZVCB%5G=RF\HM9IS%ClON(I?PQ"%M2,* MJ9;(5O-SG8U&&*{Ul!4C7>GV.G=JF%RIM;NE=E;AT&=._57KM3;]+7#"]TV MYL
Z'^W5>=COJ/W<$YA;9U"NW>RU?E"}1",0#Y*@MK5KRTE{PC$U7VT'M8 MLK#V9.&%SY)W9+=*^OFF[TGDY<8J9T/R1OY^\.SGI/JQ?]:,/"!.XJ#H
MY0&B%QU[H33P^3WB6/25P&X MJ8?1H%!R4Q8}!0&;F98L>]1B2,94|(GFP"IHR<7*AWL0F"]A=&1L[5HK78C4 MOSS<|3THU4:GY%)IE]MG\-^39O@.L.Z!02Y$;[!'?&
TJ*@Q3,L;VW? 9 M%#"7M^U5E';9*)TSG2;IDO6H=% L +L:#Z;P]VH*@;0&%7: M1L[I3$GJ/*P3:"^+K3WMP(I*MFD--4TOXSN@OZWFM;=E
M>R_2C2K^]_RRGA9V.='VH%7:K6<&7KKL6@;8>A=7IU4E5A\%G\F2^-%>;_[+9H%2F-L TB1Z9-GRZ'?FI.77/EF9=3LL"]]PI[0L]_+YUG3#-}-MQ;9I6_NO>95?[#BY^E>6W6^57<-
!C\W+^;6;O#P&D^DQF#R*FNP?@|GL59J,.MFO?XUBGAR1FAC49P%AN2;W#J$YNDT63!A>&RZP$,VH3?L+3*^;M@=!FXO+G"U9/FZZ>C9Q MS<@V;-;F L(N?ZG^?
31^7@,)!8/(GV4TT2#3GZTUOMMX MA>RO VQ/|U4(-E.\$K&9XFL-2'C=@)%EX=W&\|@ #VP6L=B!_._45)B3}+"K MF#?2L"<:1+,,0J,5PC:8!LCHI?,+[@STE29}E802PL(,DP1!X&G$$'
,"1) MW'MPYWT4K]]3)>:_,Z/?4$L#!!0 (/*!#5F7BKL

-8?2 M0$3;8T.P6BP^0"X99K>]9!:G

32- P MY1< \ !X;"]W;W)K8FlO;RYX;6S%F-]/VS 0@/\5*T_L86N3 .T3F*# M;4@(*K(?CY;;7%L+QRZV4P9_2L.RJl;..W%ZDO;V(G[Y1S?=_&,>^MN9];> MBA^M-GZ2+4-
8G8Q&OEY'*- TKNP#*P/7/K&6AGPT*U&?N5-GX)$%%H!*L;CPPU$K MEOE.-74C>F+#U%K%O$;PW^W%HULL#3!O-U*J7@(=(/&:4603H+9/#&@5Z'^HM"'006U%>0>J;>YQOOG?
277HWW7Cl/L/R>7/R M00TX6SA@W?\"4$L#!!0 (/*!#5G?(2<;D@$ /D5 3 6T-O;G1E M;G1:5?EP97++-+^+GAM,,V8S6I[",";#$7R#R+9%D
("IU+K$2!|Z.O=)WR.1l;\A%F[I]W#0NO3>,/C+FLl%J21!M] MPDDZA,2U]>+4+9F2!VE MBB&8Cl0.LTP%VGAH_l*U$&)L#4%R%7E8]>~-N$S4[J9Q18] MM%T=/N|*+6:Q1+8R]521_VV:K)?
!@;]PY[Z,Q[7*E&X2*2*F}UT:'~^-]CWO:W} M6153-;)?6O\HlZ5+%-Q9S?5N22?HD3&75Il[QRG-WJT}(X8TGFK8$R=97L1 ?l MSCl<,_V>_&K_3],//%3.K38N3,S2Y7;'D:3=0Q.$R-K5?
|2C8Y"^^^GS43CNG M_$SO<+V?VBZl>3C6+=??l?<9'_4OS"% &UL4$L! A0#% @ |H$-61RW M$)WO *P'!$ (!KP &l.$ |KP&1l0$!U!R;W!S+V-O&UL MA4$L! A0#% @ |H$-69E&P0V!R;W:W-
H965T&UL M4$L! A0#% @ \H$-66"5R%< !$!W=W$)P=EJR./I+MB?&lVlJ14$L! A0#% @ \H$-66"5R%< !0'QK !l !l@%)/! !+0X M 'AL+W=O@PO=VlJ.R:W-H965T&UL M4$L! A0#% @ \H$- M685AD!ClD@Z"

XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null;Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){else if(e.style.display){else if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html1201961false410false5 falsefalseR1.htm00000001 - Document - CoverCoverSheethttp://processapharmaceuticals.com/role/CoverCoverCover1 falsefalseR2.htm00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)Sheethttp://processapharmaceuticals.com/role/BalanceSheetsCondensed Consolidated Balance Sheets (Unaudited)Statements2 falsefalseR3.htm00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)Sheethttp://processapharmaceuticals.com/role/BalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Unaudited) (Parenthetical)Statements3 falsefalseR4.htm00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://processapharmaceuticals.com/role/StatementsOfOperationsCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)Sheethttp://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquityCondensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)Statements5 falsefalseR6.htm00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://processapharmaceuticals.com/role/StatementsOfCashFlowsCondensed Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)Sheethttp://processapharmaceuticals.com/role/StatementsOfCashFlowsParentheticalCondensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)Statements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995513 - Disclosure - Organization and Summary of Significant Accounting PoliciesSheethttp://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganization and Summary of Significant Accounting PoliciesNotes10 falsefalseR11.htm995514 - Disclosure - Stockholders??? EquitySheethttp://processapharmaceuticals.com/role/StockholdersEquityStockholders??? EquityNotes11 falsefalseR12.htm995515 - Disclosure - Stock-based CompensationSheethttp://processapharmaceuticals.com/role/Stock-basedCompensationStock-based CompensationNotes12 falsefalseR13.htm995516 - Disclosure - Net Loss per Share of Common StockSheethttp://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockNet Loss per Share of Common StockNotes13 falsefalseR14.htm995517 - Disclosure - LeasesSheethttp://processapharmaceuticals.com/role/LeasesLeasesNotes14 falsefalseR15.htm995518 - Disclosure - Related Party TransactionsSheethttp://processapharmaceuticals.com/role/RelatedPartyTransactionsRelated Party TransactionsNotes15 falsefalseR16.htm995519 - Disclosure - Commitments and ContingenciesSheethttp://processapharmaceuticals.com/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes16 falsefalseR17.htm995520 - Disclosure - Subsequent EventSheethttp://processapharmaceuticals.com/role/SubsequentEventSubsequent EventNotes17 falsefalseR18.htm995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)Sheethttp://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesOrganization and Summary of Significant Accounting Policies (Policies)Policieshttp://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies18 falsefalseR19.htm995522 - Disclosure - Stock-based Compensation (Tables)Sheethttp://processapharmaceuticals.com/role/Stock-basedCompensationTablesStock-based Compensation (Tables)Tableshttp://processapharmaceuticals.com/role/Stock-basedCompensation19 falsefalseR20.htm995523 - Disclosure - Net Loss per Share of Common Stock (Tables)Sheethttp://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTablesNet Loss per Share of Common Stock (Tables)Tableshttp://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock20 falsefalseR21.htm995524 - Disclosure - Leases (Tables)Sheethttp://processapharmaceuticals.com/role/LeasesTablesLeases (Tables)Tableshttp://processapharmaceuticals.com/role/Leases21 falsefalseR22.htm995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)Sheethttp://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeOrganization and Summary of Significant Accounting Policies (Details Narrative)Detailshttp://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies22 falsefalseR23.htm995526 - Disclosure - Stockholders??? Equity (Details Narrative)Sheethttp://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrativeStockholders??? Equity (Details Narrative)Detailshttp://processapharmaceuticals.com/role/StockholdersEquity23 falsefalseR24.htm995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetailsSchedule of Stock-based Compensation Expense (Details)Details24 falsefalseR25.htm995528 - Disclosure - Schedule of Restricted Stock Units (???RSUs???) Activity (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetailsSchedule of Restricted Stock Units (???RSUs???) Activity (Details)Details25 falsefalseR26.htm995529 - Disclosure - Stock-based Compensation (Details Narrative)Sheethttp://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrativeStock-based Compensation (Details Narrative)Detailshttp://processapharmaceuticals.com/role/Stock-basedCompensationTables26 falsefalseR27.htm995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetailsSchedule of Net Loss Per Share Basic and Diluted (Details)Details27 falsefalseR28.htm995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)Sheethttp://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrativeNet Loss per Share of Common Stock (Details Narrative)Detailshttp://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables28 falsefalseR29.htm995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetailsSchedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)Details29 falsefalseR30.htm995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetailsSchedule of Annual Lease Liabilities for all Operating Leases (Details)Details30 falsefalseR31.htm995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)Sheethttp://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetailsSchedule of Annual Lease Liabilities for all Financing Leases (Details)Details31 falsefalseR32.htm995535 - Disclosure - Leases (Details Narrative)Sheethttp://processapharmaceuticals.com/role/LeasesDetailsNarrativeLeases (Details Narrative)Detailshttp://processapharmaceuticals.com/role/LeasesTables32 falsefalseR33.htm995536 - Disclosure - Related Party Transactions (Details Narrative)Sheethttp://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrativeRelated Party Transactions (Details

Narrative)Detailshttp://processapharmaceuticals.com/role/RelatedPartyTransactions33 falsefalseR34.htm995537 - Disclosure - Commitments and Contingencies (Details Narrative)Sheethttp://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrativeCommitments and Contingencies (Details Narrative)Detailshttp://processapharmaceuticals.com/role/CommitmentsAndContingencies34 falsefalseR35.htm995538 - Disclosure - Subsequent Event (Details Narrative)Sheethttp://processapharmaceuticals.com/role/SubsequentEventDetailsNarrativeSubsequent Event (Details Narrative)Detailshttp://processapharmaceuticals.com/role/SubsequentEvent35 falsefalseAll ReportsBookAll Reports form10-q.htmpcsa-20240630.xsdpcsa-20240630_cal.xmlpcsa-20240630_def.xmlpcsa-20240630_lab.xmlpcsa-20240630_pre.xml form10-q_001.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "PCSA", "nsuri": "http://processapharmaceuticals.com/20240630", "dts": { "inline": { "local": ["form10-q.htm"] }, "schema": { "local": ["pcsa-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["pcsa-20240630_cal.xml"] }, "definitionLink": { "local": ["pcsa-20240630_def.xml"] }, "labelLink": { "local": ["pcsa-20240630_lab.xml"] }, "presentationLink": { "local": ["pcsa-20240630_pre.xml"] }, "keyStandard": 160, "keyCustom": 36, "axisStandard": 16, "axisCustom": 1, "memberStandard": 13, "memberCustom": 25, "hidden": { "total": 60, "http://fasb.org/us-gaap/2024": 39, "http://processapharmaceuticals.com/20240630": 17, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 120, "entityCount": 1, "segmentCount": 41, "elementCount": 425, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 415, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 3 }, "report": { "R1": { "role": "http://processapharmaceuticals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://processapharmaceuticals.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://processapharmaceuticals.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://processapharmaceuticals.com/OrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "995513 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://processapharmaceuticals.com/role/StockholdersEquity", "longName": "995514 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation", "longName": "995515 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock", "longName": "995516 - Disclosure - Net Loss per Share of Common Stock", "shortName": "Net Loss per Share of Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://processapharmaceuticals.com/role/Leases", "longName": "995517 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions", "longName": "995518 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies", "longName": "995519 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://processapharmaceuticals.com/role/SubsequentEvent", "longName": "995520 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"],

"reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables", "longName": "995522 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables", "longName": "995523 - Disclosure - Net Loss per Share of Common Stock (Tables)", "shortName": "Net Loss per Share of Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://processapharmaceuticals.com/role/LeasesTables", "longName": "995524 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-01-222024-01-22", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-222024-01-22", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative", "longName": "995526 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "longName": "995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)", "shortName": "Schedule of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R25": { "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "longName": "995528 - Disclosure - Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)", "shortName": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R26": { "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995529 - Disclosure - Stock-based Compensation (Details Narrative)", "shortName": "Stock-based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "PCSA:PaymentsForSettlementOfStockAwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R27": { "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "longName": "995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)", "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative", "longName": "995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)", "shortName": "Net Loss per Share of Common Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails", "longName": "995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)", "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_custom_FacilityLeaseMember", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails", "longName": "995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)", "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails", "longName": "995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)", "shortName": "Schedule of Annual Lease Liabilities for all Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://processapharmaceuticals.com/role/LeasesDetailsNarrative", "longName": "995535 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p",

"PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R33": { "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995536 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-04-012024-06-30_custom_CorLystLLCMember", "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_custom_CorLystLLCMember", "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995537 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-06-30_custom_CROsMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_custom_CROsMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative", "longName": "995538 - Disclosure - Subsequent Event (Details Narrative)", "shortName": "Subsequent Event (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-162024-07-16_us-gaap_SubsequentEventMember", "name": "us-gaap:OfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "tag": { "PCSA_ATMOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ATMOfferingMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "ATM Offering [Member]", "documentation": "ATM Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r33", "r417"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r477"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r43"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r327", "r526", "r527", "r528", "r529", "r571", "r591"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r483"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r483"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r483"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r483"] }, "PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Settlement of stock award", "documentation": "Adjustments to additional paid in capital settlement of stock awards.", "label": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Warrants issued in connection with a consulting agreement", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r5", "r17", "r64"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r448", "r459", "r469", "r494"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r451", "r462", "r472", "r497"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r483"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r490"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r452", "r463", "r473", "r490", "r498", "r502", "r510"] }, "PCSA_AllianceGlobalPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "AllianceGlobalPartnersMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Alliance Global Partners [Member]", "documentation": "Alliance Global Partners [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r455"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Antidilutive securities excluded from computation of earnings per share, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r133"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r11"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r11"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r241"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r71", "r77", "r90", "r107", "r137", "r140", "r142", "r143", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r294", "r351", "r404", "r405", "r417", "r429", "r541", "r542", "r581"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {

"http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r87", "r94", "r107", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r242", "r244", "r260", "r417", "r541", "r542", "r581"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Other Assets", "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r455"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": ["r505"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": ["r506"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r501"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r501"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": ["r501"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": ["r501"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r501"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": ["r501"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": ["r504"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r503"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r502"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r502"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Organization", "documentation": "Business Activities And Organization [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r55", "r56"] }, "PCSA_CROsMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "CROsMember", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "CROs [Member]", "documentation": "CROs [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r9", "r89", "r400"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents \u2013 Beginning of Period", "periodEndLabel": "Cash and Cash Equivalents \u2013 End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r9", "r52", "r105"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Increase in Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r52"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r481"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDisclosuresAbstract", "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r91", "r92", "r93", "r139", "r168", "r169", "r170", "r172", "r175", "r180", "r182", "r319", "r320", "r321", "r322", "r407", "r518", "r524"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r26"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Weighted average exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r183"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",

"http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares", "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r183"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r482"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r482"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r241"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r39", "r72", "r296", "r338"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r59", "r152", "r153", "r396", "r538", "r540"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Maximum equity available for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r419", "r420", "r421", "r423", "r424", "r425", "r426", "r526", "r527", "r529", "r571", "r590", "r591"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheetsParenthetical", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheetsParenthetical", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r42", "r339"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheetsParenthetical", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheetsParenthetical", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r42", "r339", "r357", "r591", "r592"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r42", "r297", "r417"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r487"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r486"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r488"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r485"] }, "PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "CompensationArrangementWithIndividualBonusAwardsGrantedPercentage", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Executive bonus percentage", "documentation": "Compensation arrangement with individual bonus awards granted percentage." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r32", "r81"] }, "PCSA_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ConsultantMember", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Consultant [Member]" } } }, "auth_ref": [] }, "PCSA_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ConsultingAgreementMember", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]", "documentation": "Consulting Agreement [Member]" } } }, "auth_ref": [] }, "PCSA_CorLystLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "CorLystLLCMember", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "CorLyst, LLC [Member]", "documentation": "CorLyst, LLC [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r16"] }, "PCSA_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Annual Lease Liabilities For All Operating Leases", "terseLabel": "Schedule Of Annual Lease Liabilities For All Financing Leases" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensation"], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r188", "r191", "r218", "r219", "r221", "r409"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r443"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r441", "r443", "r455"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"DocumentPeriodEndDate", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r442"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r430"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r443"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r443"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r476"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r433"] }, "PCSA_DueToLicensor": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "DueToLicensor", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Due to licensor", "documentation": "Due to licensor." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDiluteDetails", "http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss per Common Share - Basic", "verboseLabel": "Basic net loss per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r101", "r113", "r114", "r115", "r117", "r118", "r123", "r126", "r130", "r131", "r132", "r136", "r237", "r240", "r254", "r255", "r291", "r305", "r401"] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r126", "r127", "r130"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss per Common Share - Diluted", "verboseLabel": "Diluted net loss per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r101", "r113", "r114", "r115", "r116", "r117", "r118", "r126", "r130", "r131", "r132", "r136", "r237", "r240", "r254", "r255", "r291", "r305", "r401"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"], "lang": { "en-us": { "role": { "label": "Net Loss per Share of Common Stock", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r122", "r133", "r134", "r135"] }, "PCSA_ElionOncologyIncMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ElionOncologyIncMember", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Elion Oncology, Inc. [Member]", "documentation": "Elion Oncology, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized share based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r220"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r220"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "PCSA_EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "EmployeesAndConsultantsMember", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Employees and Consultants [Member]", "documentation": "Employees and Consultants [Member]" } } }, "auth_ref": [] }, "PCSA_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "EmployeesMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Employees [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r436"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r432"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r432"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period",

"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } }, "auth_ref": ["r517"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } }, "auth_ref": ["r432"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } }, "auth_ref": ["r514"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } }, "auth_ref": ["r455"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } }, "auth_ref": ["r432"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } }, "auth_ref": ["r432"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } }, "auth_ref": ["r432"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } }, "auth_ref": ["r432"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } }, "auth_ref": ["r515"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } }, "auth_ref": ["r5", "r85", "r98", "r99", "r100", "r108", "r109", "r110", "r112", "r117", "r119", "r121", "r138", "r146", "r147", "r148", "r184", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r277", "r304", "r311", "r312", "r313", "r327", "r381"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } }, "auth_ref": ["r484"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } }, "auth_ref": ["r440", "r459", "r469", "r494"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } }, "auth_ref": ["r445", "r456", "r466", "r491"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } }, "auth_ref": ["r490"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } }, "auth_ref": [] }, "PCSA_FacilityLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "FacilityLeaseMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Facility Lease [Member]", "documentation": "Facility Lease [Member]" } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } }, "auth_ref": ["r270", "r274"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current maturities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } }, "auth_ref": ["r270"] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/LeasesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Annual Lease Liabilities for all Financing Leases", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } }, "auth_ref": ["r578"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Non-current lease liability", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } }, "auth_ref": ["r270"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } }, "auth_ref": ["r274"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, "auth_ref": ["r274"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }, "auth_ref": ["r274"] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } }, "auth_ref": ["r578"] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: Interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } }, "auth_ref": ["r274"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of finance lease obligation", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } }, "auth_ref": ["r271", "r273"] }, "PCSA_FinancingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "FinancingLeaseLiability", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Financing lease liability", "documentation": "Financing lease liability." } }, "auth_ref": [] }, "PCSA_FirstPerformanceBasedRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "FirstPerformanceBasedRSUMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "First Performance Based RSUs [Member]", "documentation": "First Performance Based RSUs [Member]" } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt":

"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r452", "r463", "r473", "r498"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r50", "r361"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r50"] }, "PCSA_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Gross proceeds from issuance of common stock", "documentation": "Gross proceeds from issuance of common stock." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Net Operating Loss Before Income Tax Benefit", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r48", "r74", "r76", "r292", "r302", "r403", "r404", "r531", "r532", "r533", "r534", "r535"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r149", "r150", "r151", "r257", "r258", "r259", "r308", "r310", "r366", "r399", "r411", "r589"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r150", "r151", "r257", "r258", "r259", "r308", "r310", "r366", "r399", "r411", "r589"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Income Tax Benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r78", "r84", "r120", "r121", "r137", "r141", "r143", "r225", "r226", "r233", "r306", "r410"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r97", "r223", "r224", "r227", "r228", "r229", "r230", "r318"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Due to related parties", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r519", "r523"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": ["r452", "r463", "r473", "r490", "r498", "r502", "r510"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r508"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r444", "r513"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r444", "r513"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r444", "r513"] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreement", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": ["r3"] }, "PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "JanuaryOneTwoThousandTwentyFiveVestingMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "January 1, 2025 Vesting [Member]", "documentation": "January 1, 2025 Vesting [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/LeasesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r272", "r416"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseRemainingLeaseTerm", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Remaining lease term (years)", "label": "Lessee, Finance Lease, Remaining Lease Term", "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r276", "r577"] }, "PCSA_LesseeOperatingAndFinancingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "LesseeOperatingAndFinancingLeasesTextBlock", "presentation": ["http://processapharmaceuticals.com/role/Leases"], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "documentation": "Lessee Operating And Financing Leases [Text Block]", "label": "Lessee Operating And Financing Leases [Text Block]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/LeasesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Annual Lease Liabilities for all Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r578"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total
lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating
lease." } } }, "auth_ref": ["r274"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "2025", "documentation":
"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r274"] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "2024", "documentation":
"Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of
current fiscal year." } } }, "auth_ref": ["r578"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: Interest",
"label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of
discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r274"] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [
"http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": {
"role": { "label": "Remaining lease term (years)", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r276", "r577"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": {
"role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise
providing economic benefit to others." } } }, "auth_ref": ["r8", "r34", "r35", "r36", "r37", "r38", "r39", "r40", "r107", "r145", "r158", "r159", "r160", "r161", "r162", "r163",
"r164", "r165", "r166", "r243", "r244", "r245", "r260", "r337", "r402", "r429", "r541", "r581", "r582"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "label": "Liabilities
and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r47",
"r73", "r299", "r417", "r525", "r537", "r575"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label":
"LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities",
"weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Current
Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve
months or within one business cycle, if longer." } } }, "auth_ref": ["r36", "r88", "r107", "r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r243",
"r244", "r245", "r260", "r417", "r541", "r581", "r582"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrentAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current
Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesNoncurrentAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Non-current Liabilities" }
} }, "auth_ref": [] }, "PCSA_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname":
"LicenseAgreementMember", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "License
Agreement [Member]", "documentation": "License Agreement [Member]" } } }, "auth_ref": [] }, "PCSA_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://processapharmaceuticals.com/20240630", "localname": "LiquidityPolicyTextBlock", "presentation": [
"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Liquidity",
"documentation": "Liquidity [Policy Text Block]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "PCSA_MarketCapitalization": { "xbrltype": "monetaryItemType", "nsuri":
"http://processapharmaceuticals.com/20240630", "localname": "MarketCapitalization", "crdr": "debit", "presentation": [
"http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Market capitalization", "documentation": "Market
capitalization." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember",
"presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label":
"Maximum [Member]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r187", "r222", "r256", "r289", "r307", "r309", "r316", "r329", "r330", "r389", "r390", "r391", "r392",
"r393", "r397", "r398", "r406", "r407", "r408", "r412", "r413", "r414", "r415", "r418", "r543", "r583", "r584", "r585", "r586", "r587", "r588"] },
"PCSA_MaximumValueToBeSoldAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname":
"MaximumValueToBeSoldAtMarketOffering", "crdr": "debit", "presentation": [
"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Maximum value
to be sold at the market offering" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": ["r482"] }, "ecd_MeasureName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": ["r482"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r501"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": {
"en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r509"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r483"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation":
["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash
Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity
cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed,
or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r104"] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": {
"label": "Cash Flows From Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {
"http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation":
["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
"http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net
cash for operating activities from continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow)
from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or
financing activities." } } }, "auth_ref": ["r52", "r53", "r54"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } }, "auth_ref": [] }, "us-
gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 },
"http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
"http://processapharmaceuticals.com/role/StatementsOfCashFlows", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
"http://processapharmaceuticals.com/role/StatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net Loss",
"label": "Net loss", "verboseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which
is attributable to the parent." } } }, "auth_ref": ["r49", "r54", "r75", "r86", "r95", "r96", "r100", "r107", "r111", "r113", "r114", "r115", "r116", "r117", "r120", "r121", "r128",
"r145", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r237", "r240", "r255", "r260", "r303", "r359", "r379", "r380", "r427", "r541"] }, "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [
"http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "label": "Net loss available to common
stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available
to common shareholders." } } }, "auth_ref": ["r102", "r113", "r114", "r115", "r116", "r123", "r124", "r129", "r132", "r240"] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recent Accounting
Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes,
but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "PCSA_NextGenerationCapecitabineCAPMember": { "xbrltype": "domainItemType",
"nsuri": "http://processapharmaceuticals.com/20240630", "localname": "NextGenerationCapecitabineCAPMember", "presentation": [
"http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Next Generation Capecitabine - Cap [Member]",

"documentation": "Next Generation Capecitabine - Cap [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "PCSA_NonCashLeaseLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "NonCashLeaseLiabilityNet", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net", "documentation": "Non cash lease liability net." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r482"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r480"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r479"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r509"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r509"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Non-Cash Financing Activities" } } }, "auth_ref": [] }, "PCSA_OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OfferingMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Offering [Member]", "documentation": "Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Annual base salary", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": ["r522"] }, "PCSA_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current maturities of lease liabilities", "documentation": "Operating and finance lease liability current." } } }, "auth_ref": [] }, "PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "documentation": "Operating and finance lease liability noncurrent." } } }, "auth_ref": [] }, "PCSA_OperatingAndFinancingLeaseRightofUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OperatingAndFinancingLeaseRightofUseAsset", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Lease right-of-use assets, net of accumulated amortization", "documentation": "Amount of lessee's right of use underlying asset under operating and finance leases." } } }, "auth_ref": [] }, "PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OperatingAndFinancingLeaseWeightedAverageDiscountRate", "presentation": ["http://processapharmaceuticals.com/role/LeasesDetailsNarrative", "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Weighted average discount rate for our facility and equipment leases", "verboseLabel": "Operating and financing lease borrowing rate", "documentation": "Operating and financing lease weighted average discount rate." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Operating Loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r76", "r403", "r531", "r532", "r533", "r534", "r535"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Non-cash lease expense for right-of-use assets", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r576"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r270"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current maturities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r270"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Non-current lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r270"] }, "PCSA_OrganizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OrganizationAbstract", "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "auth_ref": [] }, "PCSA_OrganizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OrganizationLineItems", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "OrganizationLineItems [Line Items]" } } }, "auth_ref": [] }, "PCSA_OrganizationTable": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "OrganizationTable", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "OrganizationTable [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Due to related parties", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r35", "r417"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Income (Expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r51"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r482"] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Due from related parties", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r443"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r450", "r461", "r471", "r496"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r453", "r464", "r474", "r499"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r453", "r464", "r474", "r499"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r478"] }, "PCSA_PaymentsForSettlementOfStockAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "PaymentsForSettlementOfStockAwards", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "negatedLabel": "Settlement of stock award", "label": "Payments for settlement of stock awards", "documentation": "Payments for settlement of stock awards." } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay taxes on stock-based compensation", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r103"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r481"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r481"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r480"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r483"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r479"] }, "PCSA_PerformanceVestingCriteriaValue": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname":

"PerformanceVestingCriteriaValue", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Performance vesting criteria" } } }, "auth_ref": [] }, "PCSA_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "PlacementAgentMember", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "Placement Agent [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r480"] }, "PCSA_PotentialBaseSalaryIncreaseFinancingMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "PotentialBaseSalaryIncreaseFinancingMinimum", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Potential base salary increase financing minimum" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r437"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r439"] }, "PCSA_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "PreFundedWarrantMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Pre Funded Warrant [Member]" } } }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r41", "r168"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r41", "r339", "r357", "r591", "r592"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r521"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of stock", "verboseLabel": "Net proceeds", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "PCSA_ProceedsFromRentAndOtherCostsReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ProceedsFromRentAndOtherCostsReimbursements", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Rent and other costs reimbursements received", "documentation": "Rent and other costs reimbursements received." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r4", "r275"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r275"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r275", "r293", "r301", "r417"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r58", "r275"] }, "PCSA_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "PurchaseAgreementMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r478"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r478"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r185", "r187", "r214", "r215", "r216", "r222", "r256", "r287", "r288", "r289", "r307", "r309", "r316", "r329", "r330", "r389", "r390", "r391", "r392", "r393", "r397", "r398", "r406", "r407", "r408", "r412", "r413", "r414", "r415", "r421", "r539", "r543", "r573", "r584", "r585", "r586", "r587", "r588"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "auth_ref": ["r154", "r155", "r156", "r157", "r185", "r187", "r214", "r215", "r216", "r222", "r256", "r287", "r288", "r289", "r307", "r309", "r316", "r329", "r330", "r389", "r390", "r391", "r392", "r393", "r397", "r398", "r407", "r408", "r412", "r413", "r414", "r415", "r418", "r421", "r539", "r543", "r573", "r584", "r585", "r586", "r587", "r588"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": ["r445", "r456", "r466", "r491"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r144", "r186", "r281", "r282", "r295", "r300", "r332", "r333", "r334", "r335", "r336", "r356", "r358", "r388"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r281", "r282", "r580"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r144", "r362", "r363", "r366"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r144", "r186", "r281", "r282", "r295", "r300", "r332", "r333", "r334", "r335", "r336", "r356", "r358", "r388", "r580"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include

transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r278", "r279", "r280", "r282", "r283", "r324", "r325", "r326", "r364", "r365", "r366", "r385", "r387"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } }, "auth_ref": ["r570"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r446", "r457", "r467", "r492"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": ["r447", "r458", "r468", "r493"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": ["r454", "r465", "r475", "r500"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r11"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets", "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r44", "r64", "r298", "r314", "r315", "r323", "r340", "r417"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r85", "r108", "r109", "r110", "r112", "r117", "r119", "r121", "r146", "r147", "r148", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r248", "r249", "r251", "r253", "r268", "r269", "r311", "r313", "r327", "r591"] }, "PCSA_RightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "RightofuseAsset", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-use asset", "documentation": "Right-of-use asset." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r509"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r509"] }, "us-gaap_SalariesWagesAndOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesWagesAndOfficersCompensation", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Potential base salary increase", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "PCSA_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SalesAgreementMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sales Agreement [Member]", "documentation": "Sales Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r241"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"], "lang": { "en-us": { "role": { "label": "Schedule of Net Loss Per Share Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r530"] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": ["r10", "r12", "r126", "r127", "r130"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r4", "r275"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r30", "r31", "r362", "r363", "r366"] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r6", "r7", "r69"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r66"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r18", "r19", "r20", "r21", "r22", "r23", "r60", "r62", "r63", "r64", "r91", "r92", "r93", "r139", "r168", "r169", "r170", "r172", "r175", "r180", "r182", "r319", "r320", "r321", "r322", "r407", "r518", "r524"] }, "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "presentation": ["http://processapharmaceuticals.com/role/LeasesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases", "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]" } } }, "auth_ref": [] }, "PCSA_SecondPerformanceBasedRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SecondPerformanceBasedRSUMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Second Performance Based RSUs [Member]", "documentation": "Second Performance Based RSUs [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r431"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r435"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",

"weight": 1.0, "order": 2.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r520"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r434"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r440"] }, "PCSA_ServiceBasedRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ServiceBasedRSUMember", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Service Based RSU [Member]", "documentation": "Service Based RSU [Member]" } } }, "auth_ref": [] }, "PCSA_ServiceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ServiceBasedRestrictedStockUnitsMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Service Based RSUs [Member]", "documentation": "Service Based RSUs [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares, Beginning balance", "periodEndLabel": "Number of shares, ending balance", "label": "Number of shares, outstanding", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding." } } }, "auth_ref": [] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance", "periodEndLabel": "Weighted-average grant-date fair value per share, ending balance", "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value per share, forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value per share, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r206"] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, issued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" } } }, "auth_ref": [] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value per share, shares issued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, unvested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r203", "r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted-average grant-date fair value per share, unvested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r203", "r204"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r70"] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of shares, vested and unissued", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued." } } }, "auth_ref": [] }, "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value per share, vested and unissued", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value." } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares, vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted-average grant-date fair value per share, shares vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants, expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": ["r68"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": ["r67"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options exercisable, shares", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r197"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options exercisable weighted average exercise price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r197"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options, forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r201"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options, forfeited weighted average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r201"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercisable weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r27"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "PCSA_SharesIssuedinConnectionwithLicenseAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SharesIssuedinConnectionwithLicenseAgreementShares", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares issued in connection with license agreement, shares", "documentation": "Number of shares issued in connection with license agreement." } } }, "auth_ref": [] }, "PCSA_SharesIssuedinConnectionwithLicenseAgreementValue": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SharesIssuedinConnectionwithLicenseAgreementValue", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares issued in connection with license agreement", "documentation": "Value of shares issued in connection with license agreement." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance. shares", "periodEndLabel": "Balance. shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SharesWithheldToPayIncomeTaxOnStockbasedCompensation", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation", "documentation": "Shares withheld to pay income tax on stock based compensation.", "label": "SharesWithheldToPayIncomeTaxOnStockbasedCompensation" } } }, "auth_ref": [] }, "PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation, shares", "documentation": "Shares withheld to pay income tax on stock based compensation shares.", "label": "SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r438"] }, "PCSA_SpartanCapitalSecuritesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "SpartanCapitalSecuritesLLCMember", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"], "lang": { "en-us": { "role": { "label": "Spartan Capital Securites LLC [Member]", "documentation": "Spartan Capital Securites LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r42", "r45", "r46", "r85", "r98", "r99", "r100", "r108", "r109", "r110", "r112", "r117", "r119", "r121", "r138", "r146", "r147", "r148", "r184", "r231", "r232", "r234", "r235", "r236", "r238", "r239", "r240", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r277", "r304", "r311", "r312", "r313", "r327", "r381"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r108", "r109", "r110", "r138", "r269", "r290", "r317", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r358", "r360", "r361", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r422"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r108", "r109", "r110", "r138", "r144", "r269", "r290", "r317", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r358", "r360", "r361", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r422"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r449", "r460", "r470", "r495"] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued in connection with license agreement", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r41", "r42", "r64"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares issued in connection with capital raise, net of transaction costs, shares", "verboseLabel": "Number of shares sold", "terseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r41", "r42", "r64", "r319", "r381", "r394"] }, "us-

gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r5", "r41", "r42", "r64"] }, "PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock withheld for income taxes", "documentation": "Stock issued during period shares stock withheld for income taxes." } } }, "auth_ref": [] }, "PCSA_StockIssuedDuringPeriodSharesWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "StockIssuedDuringPeriodSharesWarrantExercised", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant exercised", "verboseLabel": " [custom:StockIssuedDuringPeriodSharesWarrantExercised-0]", "documentation": "Stock issued during period shares exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares issued in connection with capital raise, net of transaction costs", "verboseLabel": "Shares issued initial offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r41", "r42", "r64", "r327", "r381", "r394", "r428"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r28", "r41", "r42", "r64"] }, "PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor", "crdr": "credit", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor", "documentation": "Stock issued in connection with licensing agreement which had previously been recorded as due to licensor." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets", "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r42", "r45", "r46", "r57", "r341", "r357", "r382", "r383", "r417", "r429", "r525", "r537", "r575", "r591"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r61", "r106", "r167", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r184", "r252", "r384", "r386", "r395"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r65"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r267", "r285"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r267", "r285"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r267", "r285"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r267", "r285"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r267", "r285"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://processapharmaceuticals.com/role/SubsequentEvent"], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r284", "r286"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": ["r489"] }, "PCSA_ThreeYearVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "ThreeYearVestingMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "3-Year Vesting [Member]", "documentation": "3-Year Vesting [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r536", "r579"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "auth_ref": [] }, "PCSA_TitleOfInidividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "TitleOfInidividualAxis", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Title Of Inidividual [Axis]", "verboseLabel": "TitleOfInidividualAxis [Axis]" } } }, "auth_ref": [] }, "PCSA_TitleOfInidividualDomain": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "TitleOfInidividualDomain", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r481"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r488"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": ["r511"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": ["r512"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": ["r512"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r510"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": ["r510"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": ["r511"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Treasury stock shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://processapharmaceuticals.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock at cost \u2014 5,000 shares at June 30, 2024 and December 31, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r24", "r25", "r42", "r45"] }, "PCSA_TwoThousandAndNineteenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "TwoThousandAndNineteenPlanMember", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2019 Plan [Member]", "documentation": "2019 Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",

*"http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r241"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": ["r507"] }, "PCSA_UnrecognizedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "UnrecognizedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized share based compensation expense.", "documentation": "Unrecognized share based compensation expense." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r13", "r14", "r15", "r79", "r80", "r82", "r83"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r419", "r420", "r423", "r424", "r425", "r426"] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": ["r572", "r573", "r574"] }, "PCSA_WarrantsExercisableAndMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://processapharmaceuticals.com/20240630", "localname": "WarrantsExercisableAndMaturityDate", "presentation": ["http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants exercisable and maturity date", "documentation": "Warrants exercisable and maturity date." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted", "verboseLabel": "Weighted average number of common shares-diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r125", "r132"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "http://processapharmaceuticals.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic", "verboseLabel": "Weighted average number of common shares-basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r123", "r132"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://processapharmaceuticals.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r516"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-

10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1 }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2", "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6", "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2", "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r235": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r299": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/247477439/946-210-55-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "240", "Subsection": "f" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r518": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2", "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1", "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6"

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 54 0001493152-24-031622-xbrl.zip IDEA: XBRL_DOCUMENT begin 644 0001493152-24-031622-xbrl.zip M4$L#!!0 (/*!#5EE+++&&.APP*&*!++&8.APP*&*+&8.APP*&*+&8.APP&*+&8.APP

M4$L#!!0 (/*!#5EE++&&.APP< *@N * 97@S,2TO+FAT;>U:;; M-Q1]]XS-@\L,S*SQO]P %##2,B$;4.&.&#&M$B[IN0%\ L."#5
[remaining binary/base64 content]

IDEA: XBRL DOCUMENT 0001533743 2024-01-01 2024-06-30 0001533743 2024-08-01 0001533743 2024-06-30 0001533743 2023-12-31 0001533743 2024-04-01 2024-06-30 0001533743 2023-04-01 2023-06-30 0001533743 2023-01-01 2023-06-30 0001533743 us-gaap:CommonStockMember 2022-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2022-12-31 0001533743 us-gaap:RetainedEarningsMember 2022-12-31 0001533743 2022-12-31 0001533743 us-gaap:CommonStockMember 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-03-31 0001533743 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-12-31 0001533743 us-gaap:RetainedEarningsMember 2023-12-31 0001533743 us-gaap:CommonStockMember 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-03-31 0001533743 2024-03-31 0001533743 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533743 2023-01-01 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533743 2024-01-01 2024-03-31 0001533743 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533743 us-gaap:CommonStockMember 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-06-30 0001533743 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-06-30 0001533743 PCSA:ConsultingAgreementMemberPCSA:SpartanCapitalSecuritesLLCMember 2023-06-30 0001533743 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001533743 2024-01-22 2024-01-22 0001533743 2024-01-22 0001533743 2024-01-21 0001533743 PCSA:PurchaseAgreementMember 2024-01-29 2024-01-30 0001533743 PCSA:PreFundedWarrantMemberPCSA:PurchaseAgreementMember 2024-01-30 0001533743 us-gaap:WarrantMemberPCSA:PurchaseAgreementMember 2024-01-30 0001533743 2024-01-29 2024-01-30 0001533743 srt:MaximumMemberPCSA:AllianceGlobalPartnersMemberPCSA:ATMOfferingMemberPCSA:SalesAgreementMember 2024-05-21 2024-05-21 0001533743 PCSA:PurchaseAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:PreFundedWarrantMemberPCSA:PurchaseAgreementMember 2024-06-30 0001533743 us-gaap:WarrantMemberPCSA:PurchaseAgreementMember 2024-06-30 0001533743 PCSA:PlacementAgentMemberPCSA:PurchaseAgreementMember 2024-06-30 0001533743 PCSA:ElionOncologyIncMemberPCSA:LicenseAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:ConsultantMemberPCSA:ConsultingAgreementMember 2024-01-01 2024-06-30 0001533743 PCSA:EmployeesAndConsultantsMember 2024-01-01 2024-06-30 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-06-28 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-06-30 0001533743 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001533743 us-gaap:RestrictedStockMember 2024-06-30 0001533743 PCSA:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMember 2024-06-28 2024-06-28 0001533743 PCSA:EmployeesMemberPCSA:ServiceBasedRestrictedStockUnitsMemberPCSA:JanuaryOneTwoThousandTwentyFiveVestingMember 2024-06-28 2024-06-28 0001533743 PCSA:ServiceBasedRestrictedStockUnitsMemberPCSA:ThreeYearVestingMemberPCSA:EmployeesMember 2024-06-28 2024-06-28 0001533743 PCSA:EmployeesMemberPCSA:FirstPerformanceBasedRSUMember 2024-06-28 2024-06-28 0001533743 PCSA:EmployeesMemberPCSA:SecondPerformanceBasedRSUMemberPCSA:NextGenerationCapecitabineCAPMember 2024-06-28 2024-06-28 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001533743 us-gaap:WarrantMemberPCSA:OfferingMember 2024-06-30 0001533743 PCSA:ConsultingAgreementMember 2024-01-01 2024-06-30 0001533743 us-gaap:WarrantMember 2024-06-30 0001533743 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001533743 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001533743 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001533743 us-

gaap:CommonStockMember 2023-01-012023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-06-30 0001533743 PCSA:FacilityLeaseMember 2024-06-30 0001533743 us-gaap:EquipmentMember 2024-06-30 0001533743 PCSA:CorLystLLCMember 2024-04-012024-06-30 0001533743 PCSA:CorLystLLCMember 2024-01-012024-06-30 0001533743 PCSA:CorLystLLCMember 2023-01-012023-06-30 0001533743 PCSA:CorLystLLCMember 2024-06-30 0001533743 PCSA:CorLystLLCMember 2023-06-30 0001533743 PCSA:CROsMember 2024-06-30 0001533743 us-gaap:SubsequentEventMember 2024-07-162024-07-16 0001533743 us-gaap:SubsequentEventMember 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember 2024-07-162024-07-16 0001533743 PCSA:ServiceBasedRSUMemberus-gaap:SubsequentEventMember 2024-07-162024-07-16 0001533743 PCSA:FirstPerformanceBasedRSUMemberus-gaap:SubsequentEventMember 2024-07-162024-07-16 0001533743 PCSA:FirstPerformanceBasedRSUMemberus-gaap:SubsequentEventMember 2024-07-16 0001533743 PCSA:SecondPerformanceBasedRSUMemberus-gaap:SubsequentEventMember 2024-07-162024-07-16 0001533743 PCSA:SecondPerformanceBasedRSUMemberus-gaap:SubsequentEventMember 2024-07-16 iso4217:USD shares iso4217:USD shares iso4217:USD xbrli:pure 10-Qtrue2024-06-30024false001-39531Processa Pharmaceuticals, Inc.DE45-15397857380 Coca Cola DriveSuite 106HanoverMD21076443776-3133Common Stock, $0.0001 par value per sharePCSANASDAQYesYesNon-accelerated Filertruefalsefalse325694455711204706197190685492630074779745632497227625541151911460755355535120726151592760097657866439318183649953086311617189611058115078B-753690816023664489159760097657866431730444416881643244250913515801026301262220673477490-3082024-27144465-5891622-681999971698101900154915185361-3010326-2612565-5736707-6634638-3010326-2612565-5736707-6634638-1.01-1.01-1.94-1.94-2.11-2.11-5.34-5.342983283298328313468081346808272490327249031243475124347580677480720182222-5000-300000-6424756174704131951341503341504421611426320356352077-4022073-4022073123150012237811760-5000-300000-6826963410142249319123191231310875131087525-2612565-2612565112258013803417580-5000-300000-7088219991596212910001298065811111-5000-300000-7536908149891519131761167642167643155555551566282274628243050001188991891000856185613750199239924-2726381-27263812860981286872785421-5000-300000-780954628883366286098128687278542-5000-300000-780954628883661467115263115263212652008-3010326-30103262628738832878742916525000-300000-811057886023664287388328787429165-5000-300000-811057886023664-5736707-663463827842670399823202756606271580071310875980554-662984-41228-382336414699-88526-39-51359123-91559-5394713-4178539628243063520771193285612301625963663520778649232173538470619765035955571120867713350018900011804-11804

<p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zC9BccssvBck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 1 – Organization and Summary of Significant Accounting Policies</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Organization</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy ("NGC") drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split of our common stock, par value $0.0001 per share (the "Reverse Stock Split"). Pursuant to the Certificate of Amendment, our issued common stock decreased from 24,706,474 shares to 1,291,000 shares and our outstanding common stock decreased from 24,606,474 to 1,286,000. The Reverse Stock Split did not affect our authorized stock of 100,000,000 shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions of the Securities and Exchange Commission ("SEC") on Form 10-Q and Article 8 of Regulation S-X.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Liquidity</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business plans, we believe these funds will satisfy our operating needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials

for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management's experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, *Income Taxes.* Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal.

Under ACS 740-270 *Income Taxes - Interim Reporting*, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation ("FDIC") up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.

Recent Accounting Pronouncements

From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update ("ASU"). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Organization

We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy ("NGC") drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.

On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split of our common stock, par value $0.0001 per share (the "Reverse Stock Split"). Pursuant to the Certificate of Amendment, our issued common stock decreased from 24,706,474 shares to 1,291,000 shares and our outstanding common stock decreased from 24,606,474 shares to 1,286,000 shares. The Reverse Stock Split did not affect our authorized common stock of 100,000,000 shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions of the Securities and Exchange Commission ("SEC") on Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Liquidity

Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $

...$81.1 million at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $5.7 million and used $5.4 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.

We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of our common stock.

In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.

At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current business plans, we believe these funds will satisfy our operating needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding transactions. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

*_Use of Estimates_*

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management's experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

*_Income Taxes_*

We account for income taxes in accordance with ASC Topic 740, *Income Taxes.* Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal.

Under ACS 740-270 *Income Taxes - Interim Reporting,* we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.

*_Concentration of Credit Risk_*

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation ("FDIC") up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.

*_Recent Accounting Pronouncements_*

From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update ("ASU"). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Note 2 – Stockholders' Equity

*_Preferred Stock_*

There were ...

...issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023.

Common Stock

During the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the "Pre-Funded Warrants"), and warrants to purchase up to 1,555,555 shares of our common stock (the "Common Warrants") in a public offering (the "Offering"). The Common Warrants have an exercise price of $4.50 , are immediately exercisable and expire on January 30, 2029 . The shares of common stock were offered at a combined public offering price of $4.50 per share and accompanying Common Warrant and $4.4999 per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $0.0001 and were exercised in full simultaneously with the closing of the Offering in exchange for 1,079,555 shares of our common stock. Gross proceeds in connection with the Offering were $7.0 million. We received $6.3 million in net proceeds from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement agent warrants to purchase 62,222 shares of common stock, exercisable at $5.625 per share that expire on February 1, 2027 .

During the six months ended June 30, 2024, we also issued: 5,000 shares of common stock to Elion Oncology, Inc. ("Elion") in satisfaction of the third milestone event under the license agreement; 10,000 shares of common stock to a consultant in accordance with their consulting agreement; and 12,328 shares of common stock to certain employees and consultants, net of 5,015 shares of common stock withheld for income taxes owed upon distribution of the shares.

000476000107955515555554.502029-01-304.504.49990.000110795557000000.06300000622225.6252027-02-01500010000123285015

Note 3 - Stock-based Compensation

On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of 800,000 shares of our common stock. At June 30, 2024, we have 503,129 shares available for future grants.

Stock Compensation Expense

We recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:

Schedule of Stock-based Compensation Expense

| | Three Months Ended June 30, | | | | Six Months Ended June 30, | | | |
	2024		2023		2024		2023	
Research and development	$	45,583		102,678		76,704	$	209,526
General and administrative		107,049		216,445		243,571		451,101
Total	$	152,632						

left		$	319,123		$	320,275		$	660,627	

Stock Options

Stock options to purchase 4,245 shares of common stock with a weighted-average exercise price of $336.00 expired during the six months ended June 30, 2024. At June 30, 2024, we had outstanding and exercisable options for the purchase of 2,747 shares with a weighted average exercise price of $409.09 and a weighted average remaining contractual life of 4.2 years. At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock options.

Restricted Stock Awards

During the six months ended June 30, 2024, we vested 1,250 Restricted Stock Awards ("RSAs") with a weighted average grant-date fair value of $9.26 per share. We had no RSAs outstanding at June 30, 2024.

Restricted Stock Units

Activity with respect to our Restricted Stock Units ("RSUs") during the six months ended June 30, 2024 was as follows:

	Number of shares	Weighted- average grant-date fair value per share
Outstanding at January 1, 2024	222,722	$ 45.82
Granted	39,202	2.24
Forfeited	(10,775)	58.37
Issued	(12,328)	99.86
Outstanding at June 30, 2024	238,821	35.31
Vested and unissued	143,793	50.71
Unvested at June 30, 2024	95,028	$ 12.00

On June 28, 2024, we granted RSUs for the future issuance of 39,202 shares of common stock to our employees which vest accordingly: RSUs for the future issuance of

AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zakKaOLh1Cci" title="Number of shares, granted">14,969 shares of common stock vest on January 1, 2025; RSUs for the future issuance of 18,173 shares of common stock vest over a three-year period upon meeting service requirements; RSUs for the future issuance of 3,030 shares of common stock vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of 3,030 shares of common stock vest upon dosing the first patient in our Phase 2 study in NGC-Cap.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At June 30, 2024, unrecognized stock-based compensation expense of approximately $538,000 for RSUs is expected to be fully recognized over a weighted average period of 1.7 years. The unrecognized expense excludes approximately $420,000 of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase 1,617,777 shares of common stock as part of the Offering (see Note 2). Warrants to purchase 5,000 shares of our common stock expired unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of 15,000 shares of our common stock in exchange for a payment of $10,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">At June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of 1,778,284 shares with a weighted average exercise price of $6.17 and a weighted average remaining contractual life of4.3 years. All the outstanding stock purchase warrants are exercisable as of June 30, 2024. We did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> </p> 800000503129<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbG5O5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"> Schedule of Stock-based Compensation Expense</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">

		Three Months Ended June 30,		Six Months Ended June 30,	
		2024	2023	2024	2023
Research and development		$45,583	$102,678	$76,704	$209,526
General and administrative		107,049	216,445	243,571	451,101
Total		$152,632	$319,123	$320,275	$660,627

45583102678767042095261070492164452435714511011526323191233202756606274245336.002747409.09P4Y2M12D12509.260<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Activity with respect to our Restricted Stock Units ("RSUs") during the six months ended June 30, 2024 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> Schedule of Restricted Stock Units ("RSUs") Activity</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">

	Number of shares	Weighted- average grant-date fair value per share
Outstanding at January 1, 2024		

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" style="width: 18%; text-align: right" title="Number of shares, Beginning balance">222,722</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__2gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" style="width: 18%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">45.82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" style="text-align: right" title="Number of shares, granted">39,202</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__202gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" style="text-align: right" title="Weighted-average grant-date fair value per share, granted">2.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0jJvl" style="text-align: right" title="Number of shares, forfeited">(10,775</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__2024063gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">58.37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, issued">(12,328</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__202gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, shares issued">99.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" style="text-align: right" title="Number of shares, ending balance">238,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__2gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">35.31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued">143,793</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c2024063gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">50.71</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">95,028</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested">12.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

22272245.82392022.241077558.371232899.8623882135.3114379350.719502812.00392021496918173303030530538000P1Y8M12D42000016177775000150001000017782846.1id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zEFPoujgZDxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note 4 - Net Loss per Share of Common Stock</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net Loss Per Share</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> Schedule of Net Loss Per Share Basic and Diluted</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30, </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,010,326</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,612,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,736,707</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(6,634,638</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">2,983,283</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,346,808</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,724,903</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,243,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td>

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Basic and diluted net loss per share	$(1.01)	$(1.94)	$(2.11)	$(5.34)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Weighted-average number of common shares outstanding - basic and diluted	2,849,192	1,217,095	2,590,530	1,114,324
Weighted-average number of vested RSUs– basic and diluted	134,091	129,713	134,373	129,151
Weighted-average number of common shares-basic and diluted	2,983,283	1,346,808	2,724,903	1,243,475

Our diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded 1,876,059 and 254,314 of potentially dilutive common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended.

The computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:

Schedule of Net Loss Per Share Basic and Diluted

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Three Months Ended June 30,				

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Basic and diluted net loss per share				
Net loss available to common stockholders	$(3,010,326)	$(2,612,565)	$(5,736,707)	$(6,634,638)
Weighted average number of common shares-basic and diluted	2,983,283	1,346,808	2,724,903	1,243,475
Basic and diluted net loss per share	$(1.01)	$(1.94)	$(2.11)	$(5.34)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Weighted-average number of common shares outstanding - basic and diluted	2,849,192	1,217,095	2,590,530	1,114,324
Weighted-average number of vested RSUs- basic and diluted	134,091	129,713	134,373	129,151
Weighted-average number of common shares-basic and diluted	2,983,283	1,346,808		

2,724,903

1,243,475

-3010326-2612565-5736707-66346382983283298328311346808134680827249032724903124347512434751243475-1.01-1.01-1.94-1.94-2.11-2.11-5.34-5.342849192284919212170951217095259053025905301114324111432413409113409112971312971313437313437312915112915129832832983283113468081346808272490372724903

Note 5 – Leases

We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% in determining the present value of the lease payments based on the information available at the lease commencement date.

Lease costs included in our condensed consolidated statements of operations totaled approximately $23,000 and $24,000 for the three months ending June 30, 2024 and 2023, respectively, and approximately $45,000 and $49,000 for the six months ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as follows at June 30, 2024:

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases

Remaining lease term (years) for our facility lease	1.3
Remaining lease term (years) for our equipment lease	1.6
Weighted average discount rate for our facility and equipment leases	8.0%

Annual lease liabilities for the operating lease were as follows at June 30, 2024:

Schedule of Annual Lease Liabilities for all Operating Leases

2024	$45,797
2025	70,040
Total lease payments	115,837
Less: Interest	(6,511)
Present value of lease liabilities	109,326
Less: current maturities	(87,495)
Non-current lease liability	$21,831

Annual lease liabilities for the financing lease were as follows at June 30, 2024:

Schedule of Annual Lease Liabilities for all Financing Leases

2024	$3,232
2025	6,820
2026	488
Total lease payments	10,540
Less: Interest	(1,037)
Present value of lease liabilities	9,503
Less: current maturities	(5,686)
Non-current lease liability	$3,817

0.0823000240004500049000

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases

Remaining lease term (years) for our facility lease	1.3
Remaining lease term (years) for our equipment lease	1.6

Weighted average discount rate for our facility and equipment leases — 8.0%

Annual lease liabilities for the operating lease were as follows at June 30, 2024:

Schedule of Annual Lease Liabilities for all Operating Leases

2024	$	45,797
2025		70,040
Total lease payments		115,837
Less: Interest		(6,511)
Present value of lease liabilities		109,326
Less: current maturities		(87,495)
Non-current lease liability		21,831

Annual lease liabilities for the financing lease were as follows at June 30, 2024:

Schedule of Annual Lease Liabilities for all Financing Leases

2024	$	3,232
2025		6,820
2026		488
Total lease payments		10,540
Less: Interest		(1,037)
Present value of lease liabilities		9,503
Less: current maturities		(5,686)
Non-current lease liability	$	3,817

Note 6 – Related Party Transactions

CorLyst, LLC ("CorLyst") reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded approximately $27,000 and $34,000 of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $50,000 and $64,000 for the six months ended June 30, 2024 and 2023, respectively. No amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst is a shareholder.

Note 7 – Commitments and Contingencies

Purchase Obligations

We enter into contracts in the normal course of business with contract research organizations ("CROs") and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $14.3 million of future services under the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining clinical trials.

Note 8 – Subsequent Event

On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). Mr. Skibsted has nearly 30 years of experience in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base salary increase upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target bonus of 35% of his base compensation. In addition, the Compensation Committee awarded 28,000 RSUs to Mr. Skibsted, which vest accordingly: 14,000 RSUs vest on July 16, 2025;

shares, granted">7,000 RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa's outstanding shares of stock at the then current market price) of at least $30 million; and 7,000 RSUs vest upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment agreement.</p> 40000050000150000000.35280001400070003000000070001500000falsefalsefalse"